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ABSTRACT 
Achieving effective drug concentrations within the central nervous system (CNS) 
remains one of the greatest challenges for the treatment of brain tumors. The presence of 
the blood-brain barrier and blood-spinal cord barrier severely restricts the blood-to-CNS 
entry of nearly all systemically administered therapeutics, often leading to the 
development of peripheral toxicities before a treatment benefit is observed. To 
circumvent systemic barriers, intrathecal (IT) injection of therapeutics directly into the 
cerebrospinal fluid (CSF) surrounding the brain and spinal cord has been used as an 
alternative administration route; however, its widespread translation to the clinic has 
been hindered by poor drug pharmacokinetics (PK), including rapid clearance, 
inadequate distribution, as well as toxicity.  One strategy to overcome the limitations of 
free drug PK and improve drug efficacy is to encapsulate drug within nanoparticles (NP), 
which solubilize hydrophobic molecules for sustained release in physiological 
environments. In this thesis, we will develop NP delivery strategies for brain tumor 
therapy in two model systems: glioblastoma (GBM), the most common and deadly 
malignant primary brain tumor, and medulloblastoma, the most common pediatric brain 
tumor. In the first research chapter, we developed 120 nm poly(lactic acid-co-glycolic 
acid) NPs encapsulating the chemotherapy, camptothecin, for intravenous delivery to 
GBM. NP encapsulation of camptothecin was shown to reduce the drug’s toxicity and 
enable effective delivery to orthotopic GBM. To build off the success of intravenous NP, 
the second research chapter explored the utility of 100 nm PEGylated NPs for use with 
IT administration. Using in vivo imaging and ex vivo tissue slices, we found the NPs 
were rapidly transported by the convective forces of the CSF along the entire neuraxis 
and were retained for over 3 weeks. Based on their wide spread delivery and prolonged 
circulation, we examine the ability of the NPs to localize with tumor lesions in a 
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leptomeningeal metastasis (LM) model of medulloblastoma. NPs administered to LM 
bearing mice were shown to penetrate into LM mets seeded within the meninges around 
the brain. These data show the potential to translate our success with intravenous NPs 
for GBM to improve IT chemotherapy delivery to LM.  
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Introduction 
1.1. Nanoparticle Drug Carriers  
Nanoparticles (NP) are colloidal particles ranging in size from 1 to 1000 nm and 
can be formulated from a variety of diverse materials, including metals2–4, proteins5,6, 
lipids7,8, viral vectors9, and polymers10–12. The ability to alter and tune their biophysical 
and biochemical properties has made them a versatile asset in modern medicine and 
particularly appealing as carriers for therapeutic drug delivery. Due to their favorable 
biocompatibility and low toxicity, organic polymers and lipids have led the field for NP 
drug delivery in the clinic13–15. Polymeric and lipid based NPs also have the potential to 
encapsulate and release a wide range of therapeutics, including hydrophilic and 
hydrophobic small molecule drugs, proteins, and gene therapies16.  
Loading a drug into a NP can offer distinct and significant advantages over 
utilizing its free form counterpart. While the biophysical properties of many potential 
drug candidates restrict their compatibility with most or all administration routes, NPs 
are relatively easily formulated for administration by oral, local, topical, intranasal, and 
parenteral (intravenous, intramuscular, subcutaneous) routes, with intravenous (IV) 
administration being the most extensively studied, both clinically and preclinically. For 
example, paclitaxel’s water insolubility is incompatible with IV administration, but 
solubilization of paclitaxel within albumin 17 or poly(lactic acid)-co-poly(ethylene 
glycol)18 NPs enables IV injection and improves both its tolerability and efficacy. The 
solubilization of drugs within the NP matrix also restricts the interaction of the drug with 
the body until the drug is released from the NP. This helps protect the body from 
unwanted side effects associated with the drug, and it protects the drug, especially 
proteins and genes, from becoming inactivated or degraded within the physiological 
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environment19,20. For example, while free doxorubicin, a potent chemotherapy, is 
effective across numerous tumor types, use of doxorubicin is associated with severe 
cardiotoxicity21. Doxil, a doxorubicin-loaded liposome, maintains the drug’s efficacy but 
significantly lowers the risk for cardiac toxicity and allows for more opportunities for 
combination treatments22. Importantly, Doxil and many NP formulations also exhibit 
prolonged circulation compared to their free drug form23–25. Thus, drug encapsulation 
within NPs can improve efficacy and tolerability through multiple mechanisms, 
depending on the limitations imposed by the drug’s biophysical properties. 
1.1.1. Nanoparticle Design Considerations 
To maximize the benefit of NP encapsulation, the biophysical properties of the 
nanocarrier itself must be considered. The ideal set of NP properties for a given drug will 
change depending on the barriers presented to the NP based on target tissue and 
delivery route. Despite these differences, across tissues and administration routes, the 
size of the NP, surface charge, mechanism of drug release and targeting are key design 
considerations known to drastically alter the efficacy of NP therapies26–29.  
NP size is well documented to be a critical biophysical property governing the fate 
of NPs following administration by most routes, including IV30–32, oral33,34, 
intranasal35,36, and convection enhanced delivery (CED)37,38. The extent and manner by 
which size affects distribution for each route varies greatly, including the size range that 
would be expected to optimize NP distribution. For example, NP size has a particularly 
strong effect on the rate of NP clearance following IV injection32,39,40, which in turn can 
significantly alter organ localization31. A NP size between 30 and 150 nm is typically 
considered ideal for IV administration. This is due to relatively strict size cutoffs imposed 
by the filtration organs and immune system. At the lower end, NPs <10 nm in size are 
rapidly filtered by the kidneys for renal excretion, while NPs in the 10-20 nm range 
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experience accelerated liver filteration40.  Above 200 nm, NPs circulation is significantly 
reduced due to increased phagocytosis and clearance by the reticulo-endothelial 
system41. Comparatively, size has shown a relatively minimal effect on orally 
administered NPs. Since the GI tract does not exhibit size dependent clearance 
mechanisms that are observed for intravenous routes of delivery, the clearance and 
overall efficacy of orally administered NPs is reported to be more dependent on the 
mucoadhesive surface properties of the NP34. However, given the same adhesion 
properties,  decreasing NP size can improve efficacy via better penetration through the 
mucosal lining of the intestines33. NP size is known to alter NP distribution, regardless of 
delivery route, and engineering the best NP requires understanding the magnitude and 
types of effects imposed. 
Surface charge (zeta potential) is a key parameter dictating NP interactions with 
proteins and cells for all routes of administration. Applications requiring high 
intracellular NP delivery, like gene therapy, favor the use of cationic NPs, which promote 
cellular uptake due to the negative charge of cellular membrane lipids42,43. Similarly, 
cationic NPs are desired for intranasal and oral administration, where the positive 
charge significantly prolongs their retention within the negatively charged mucus of the 
nose and GI tract34,44,45. In contrast, the success of IV and CED administered NP heavily 
relies on their ability to avoid non-specific cellular and protein interactions38,46–50. 
Generally, a large positive or negative surface charge promotes NP-protein interactions, 
while a near neutral (-10 to +10 mV) charge significantly reduces protein adsorption51,52. 
Thus, NPs are frequently surface coated with poly(ethylene glycol) or other molecules to 
create a hydrophilic, near neutral layer around the NP, which can improve the 
distribution of NPs administered by either CED or IV. CED utilizes the convective forces 
of the infusion to drive NP movement through the extracellular space.  The addition of a 
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dense PEG layer significantly reduces NP-extracellular matrix interactions, enabling the 
NPs to reach a larger volume of distribution47,50. For IV NPs, the adsorption of serum 
proteins, especially opsonins, to the NP surface increases the phagocytosis and clearance 
of NPs by the mononuclear phagocyte system. PEGylated surfaces resist the deposition 
of these proteins on the NP surface, which leads to significantly longer circulation times 
compared to their non-PEGylated counterparts46,53,54. For example, Klibanov et al. 
showed PEGylation of their liposomal nanoparticles increased the circulation half-life 
from 30 min to 5 hours24. These results exemplify the potent effects of surface properties 
on the NP’s interaction with the cells and proteins of its environment and the resulting 
changes to their distribution.  
Further modifications to the NP surface with peptides50,55–57, aptamers58–60 and 
antibodies61–63 can be employed to increase NP interactions with a specific target. The 
efficacy of these targeting strategies is thought to be determined by a combination of 
factors, including the specificity and affinity of the moiety for its target, how unique the 
target is to the cell or tissue of interest, and accessibility of the NP to the target28,55,64. 
Technologies like bacteriophage biopanning and systematic evolution of ligands by 
exponential enrichment (SELEX), along with advances in antibody design, have allowed 
for the identification of new moieties with high affinity and specificity for unique 
targets65–68. Incorporation of targeting ligands onto the surface of NP can improve NP 
efficacy through increase carrier retention and payload delivery within specific 
tissues65,69,70, enhance NP internalization71,72 or direct NP fate to specific intracellular 
organelles73,74.  Although NP size and surface charge are thought to have the greatest 
effect on overall NP distribution, the addition of targeting ligands has received 
significant attention to improve NP specificity, reduce off-target delivery and overcome 
biological barriers to NP delivery.  
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The efficacy of NPs relies upon efficient release of drug at the target site. In the 
ideal scenario drug would only be released after reaching the desired target tissue. 
Towards this goal, drug release from NP carriers can be modified to occur passively over 
minutes to weeks75–79. If the drug release is too rapid, the benefit of prolonged NP 
circulation is lost. If the release is too slow, the NPs will be cleared before the therapy is 
delivered. For example, cisplatin-loaded liposomes showed reduced off target side effects 
and nearly 5-fold increased tumor accumulation compared to free cisplatin80, which 
would be expected to provide improved efficacy. However, the rate of cisplatin release 
from the liposomes was so slow that a therapeutically relevant concentration of free drug 
is not achieved within the tumor. Thus to engineer NP drug systems for maximal 
efficacy, it is necessary tune drug release with an understanding of the pharmacokinetics 
of the carrier itself.  
Despite extensive studies to characterize the key NP biophysical parameters 
necessary to enable successful IV administration and improve drug distribution, NP 
design and use for intrathecal (IT) administration remains poorly characterized. 
Polymeric and liposomal drug carriers have been utilized successfully for IT therapy to 
overcome the rapid clearance of hydrophilic therapies81–86, although most studies were 
centered on their use as sustained release depots for local delivery to injured spinal cord. 
In the context of chemotherapies, DepoCyt, a 10 µm liposomal system, is FDA approved 
(1999) for lymphomatous meningitis from leukemia. DepoCyt successfully provides 
sustained release of cytarabine, requiring only a single injection every 2 weeks compared 
to twice weekly for free drug. However, it does not alter cytarabine’s overall distribution 
along the neuraxis, which is reflected in its equivalent clinical treatment response 
compared to free drug101,110–113.  DepoCyt’s large microscopic size means its efficacy must 
rely on the release and subsequent movement of the drug to the cancer cells, limiting its 
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utility for delivering lipophilic compounds. These studies show the feasibility and safety 
of drug carriers for IT administration, but additional work is needed to characterize the 
effects of key biophysical properties on NP distribution after IT injection. 
1.2. Cerebrospinal Fluid System 
The cerebrospinal fluid (CSF) system includes the cerebral ventricles, 
perivascular spaces, and the brain and spinal cord subarachnoid spaces. The 
subarachnoid space (SAS) lies between the arachnoid and pia mater meninges and is 
spanned by a mesh-like network of collagen trabeculae92,93. CSF is a clear, mainly 
acelluar, electrolyte rich fluid produced by the choroid plexus within the lateral 
ventricles of the brain. The flow of CSF out through the 4th ventricle into the cisterna 
magna and throughout the SAS plays a critical role in maintaining homeostasis through 
regulation of electrolytes, transport of neuro-active molecules, and elimination of 
metabolites93–95 . The pulsatile forces generated by our cardiac and respiratory cycles 
cause an ebb and flow movement of the CSF, while interactions with microanatomies of 
the SAS, such as trabeculae and nerves, are thought to produce local vortices of CSF 
mixing92,96–98. CSF exits the SAS into the periphery either directly into blood through the 
arachnoid villi, or into the lymphatic system through the nasal cribriform plate and along 
spinal nerve roots94. The constant production and adsorption of CSF leads to complete 
turnover of the CSF volume 4 times per day in humans, and 12 times per day in mice95,99. 
Although CSF is rapidly turned over, the circulation of CSF throughout the entire CNS 
maintains it as an attractive delivery medium for neurological therapies. 
1.3.  Leptomeningeal Metastasis in Medulloblastoma 
Medulloblastoma (MB) arises in the cerebellum and is the most common 
malignant pediatric brain tumor100. The overall 5-year survival across all 4 
medulloblastoma (MB) subtypes is about 85%, but survival drops to 60% for patients 
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exhibiting leptomeningeal metastasis (LM). LM is characterized by the spread of tumor 
cells through the cerebrospinal fluid (CSF) to the meninges surrounding the brain and 
spinal cord100–102. The Group 3 subtype of MB has the highest incidence of LM at 
approximately 50% and is also associated with the lowest 5-year survival at only 32%100. 
Because LM is not typically accessible for resection, treatment consists of a combination 
of one or more modalities, including radiation, intrathecal (IT) chemotherapy, and high-
dose systemic chemotherapy. Although radiation of the cerebellar-spinal axis improves 
survival outcomes, severe long-term side effects, including cognitive deficits, endocrine 
disorders, and secondary malignancies, have driven efforts to reduce radiation doses in 
favor of other treatments103–105. Similarly, debilitating peripheral organ toxicities often 
occur from the high-doses of chemotherapy required to overcome the limited central 
nervous system (CNS) penetration of systemic agents past the blood-brain and blood-
CSF barriers106,107. Thus, new therapies for the treatment of LM are desperately needed to 
reduce peripheral chemotherapy and CNS radiation related toxicities. 
1.4. Intrathecal Chemotherapy 
IT chemotherapy is an appealing alternative to IV or oral administration for LM 
therapy, since compounds administered IT bypass the blood-CSF barrier and achieve 
high drug concentrations within the CSF at a fraction of the systemic dose108,109. 
Additionally, the continuous pulsatile movement of the CSF throughout the SAS 
provides convective forces to disburse drugs along the neuraxis96–98,110, where they would 
have potential to directly interact with LM lesions. However, the widespread adoption of 
IT administration for chemotherapy has been significantly limited by the incompatibility 
of most potential drug candidates due to their biophysical properties111–113.  
Chemotherapies suitable for intrathecal administration are described to require a 
lack of neurotoxicity following systemic administration and adequate water solubility for 
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injection114–116. Currently, only four chemotherapies are FDA approved for IT 
administration, specifically for the treatment of leukemia that has spread to the CNS117–
120. Two therapies, methotrexate and cytarabine, are often used off-label in the treatment 
of MB, mainly due to their compatibility with IT use. Methotrexate and cytarabine work 
as antimetabolites for nucleotides to inhibit DNA replication but are only effective in the 
S-phase of the cell cycle. While their hydrophilicity enables them to be distributed by 
CSF movement, it also results in their rapid clearance with the turnover of CSF95,121. 
Their mechanism of action and cell cycle dependency require prolonged high 
concentrations exposure to kill cancer cells. In order to maintain of adequate 
concentrations of hydrophilic chemotherapies, patients must receive lumber injections 
2-3x per week or have an additional invasive surgery to implant a subcutaneous 
Ommaya Reservoir with an intraventricular catheter91,119. Still, the clinical benefit of 
current IT chemotherapy for treating LM is debated116,122. 
Lipophilic chemotherapies are typically incompatible with IT administration due 
to toxicity and lack of efficacy116,119,123. Both phenomena are believed to result from a lack 
of distribution away from the injection site. Their lipophilicity causes the drugs to rapidly 
get cleared to systemic circulation or enter nearby parenchymal cells before they can be 
distributed by the CSF124,125. Incompatibility with IT administration severely limits the 
chemotherapy options available for the treatment of LM, and new technologies are 
desperately needed to overcome the pharmacokinetic limitations of lipophilic 
chemotherapies. 
1.5. Overview and Specific Aims 
The versatility of NP properties allows them to be rationally designed for the 
encapsulation of a wide range of therapeutics and their subsequent delivery by nearly 
any administration route. In this work, we aim to develop NP delivery strategies for the 
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treatment of 2 brain tumor models, glioblastoma and medulloblastoma. The first 
research chapter we focus on the development of an intravenous NP system for delivery 
to orthotopic glioblastoma. In the second and third chapters, we aim to build upon the 
success and lessons learned from the use of intravenous NPs to begin to elucidate the key 
parameters in deciding NP fate after IT administration. Our central hypothesis is IT 
administered NPs will be transported by the convective flow of CSF to enable wide 
spread delivery along the neuraxis and to LM, and that NP fate will depend upon NP size 
and surface properties. The long-term goal of these studies is to define the key NP 
biophysical properties to enable effective IT delivery of lipophilic chemotherapies for the 
treatment of LM in MB. We address this hypothesis in the following chapters through 
the testing of these specific aims: 
1.5.1. Specific Aim 1 
Test the capacity of NPs to solubilize and enable the effective IV delivery of an 
otherwise intolerable lipophilic chemotherapy. 
1.5.2. Specific Aim 2 
Characterize the ability of NPs to be distributed by the convective flow of CSF to 
identify engineering opportunities for the design of IT NP systems.  
1.5.3. Specific Aim 3 
Identify a targeting ligand for LM cells and investigate the ability of targeting to 
alter NP fate after CSF administration. 
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Intravenous Delivery of Camptothecin-loaded PLGA Nanoparticles for the 
Treatment of Intracranial Glioma 
2.1. Abstract  
Effective treatment of glioblastoma multiforme remains a major clinical 
challenge, due in part to the difficulty of delivering chemotherapeutics across the blood-
brain-barrier. Systemically administered drugs are often poorly bioavailable in the brain, 
and drug efficacy within the central nervous system can be limited by peripheral toxicity. 
Here, we investigate the ability of systemically administered poly (lactic-co-glycolic acid) 
nanoparticles (PLGA NPs) to deliver hydrophobic payloads to intracranial glioma. 
Hydrophobic payload encapsulated within PLGA NPs accumulated at ~10x higher levels 
in tumor compared to healthy brain. Tolerability of the chemotherapeutic camptothecin 
(CPT) was improved by encapsulation, enabling safe administration of up to 20mg/kg 
drug when encapsulated within NPs. Immunohistochemistry staining for γ-H2AFX, a 
marker for double-strand breaks, demonstrated higher levels of drug activity in tumors 
treated with CPT-loaded NPs compared to free drug. CPT-loaded NPs were effective in 
slowing the growth of intracranial GL261 tumors in immune competent C57 albino mice, 
providing a significant survival benefit compared to mice receiving saline, free CPT or 
low dose CPT NPs (median survival of 36.5 days compared to 28, 32, 33.5 days 
respectively). In sum, these data demonstrate the feasibility of treating intracranial 
glioma with systemically administered nanoparticles loaded with the otherwise 
ineffective chemotherapeutic CPT. 
2.2. Introduction 
Malignant gliomas are the most common form of primary brain tumors, afflicting 
as many as 12,000 patients per year in the United States126,127. Glioblastoma multiforme 
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(GBM) tumors, a grade IV astrocytoma, are distinguished by their fast growing and 
infiltrative nature. Even after aggressive treatment, which includes tumor resection, 
radiation, and chemotherapy, the median survival for patients diagnosed with GBM is 
only 12-14 months 128, and few new treatments have advanced to the clinic in the past 
three decades.  
One major challenge to achieving better treatment of GBM is the difficulty of 
delivering drugs across the blood-brain barrier (BBB), a network of endothelial cells that 
present both active and passive barriers to the uptake of systemically delivered agents. 
Chemotherapeutics capable of crossing the BBB are typically poorly soluble and may 
clear rapidly, and thus high systemic doses are needed to achieve efficacy. This large 
systemic dose can often have severe toxic effects on peripheral tissue and organs before a 
treatment benefit is observed.  
Thus, many drugs that could be of interest for treating GBM cannot be delivered 
in doses that are both effective and safe. For example, camptothecin (CPT), a potent 
DNA damaging chemotherapeutic, is effective at killing cells in vitro, but failed in clinical 
trials due to dose-limiting toxicities and, ultimately, poor efficacy. CPT is rapidly 
hydrolyzed at physiological pH from its active lactone form to a 10-fold less active, more 
toxic carboxylate form, which is cleared rapidly once bound to plasma proteins 129.  
Encapsulation of therapeutics such as CPT in polymeric or liposomal 
nanoparticles is a one strategy that could be used to improve drug action. Drug that has 
been encapsulated is effectively solubilized and protected from degradation, which 
prolongs circulation time and increases bioavailability. For example, poly (lactic-co-
glycolic acid) (PLGA) is a biocompatible and biodegradable polymer that can be formed 
into nanoparticles for encapsulation and sustained release of drug payloads. PLGA 
nanoparticles are capable of encapsulating a wide range of active agents for sustained 
12 
 
release in biological environments, including CPT  130–132. CPT potency is improved by 
encapsulation and sustained release when infused directly into tumors 19,133. However, 
the question of whether CPT-loaded PLGA nanoparticles are capable of treating tumors 
within the brain when administered intravenously remains unanswered. 
 The goal of this work was to evaluate the ability of systemically 
administered CPT-loaded PLGA NPs to treat intracranial GBM in mice. GL261 is a 
syngeneic mouse glioma cell line that mimics many of the proliferative, invasive, and 
diffuse characteristics of human GBM 134,135. The use of luciferase expressing GL261 cells 
allows us to track tumor growth in vivo with bioluminescence and, therefore, NP efficacy 
in immune-competent C57BL/6 albino mice. Nanoparticles were administered to mice 
bearing orthotopic GL261-Luc2 tumors to evaluate specific payload delivery to tumor, 
peri-tumor, and healthy brain tissue. Efficacy of free CPT versus CPT encapsulated at 
two doses was determined by tumor growth and survival to test the hypothesis that 
encapsulation of chemotherapeutic in a nanoparticle could improve systemic therapy of 
orthotopic GBM. 
2.3. Materials and Methods 
 Materials  
Camptothecin (CPT), 1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindotricarbocyanine 
Iodide (DiR), dichloromethane (DCM), methanol, dimethyl sulfoxide (DMSO), 10% 
neutral buffered formalin, E-TOXA-Clean and polyvinyl alcohol (PVA) were all 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Ester terminated poly (lactic-co-
glycolic acid) (PLGA) (50:50; inherent viscosity = 0.59 dL/g) was obtained from Lactel 
(Birmingham, AL, USA). All water used in nanoparticle fabrication was endotoxin free 
(<0.0050 EU/ml) purchased from G-biosciences (St. Louis, MO, USA). Dulbecco’s 
modified Eagle medium (DMEM), fetal bovine serum (FBS), 0.25% trypsin-EDTA and 
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geneticin selective antibiotic (G-418) were purchased from Gibco Invitrogen (Carlsbad, 
CA, USA). Greiner T25 tissue culture flasks with filter cap and Costar 96 well assay plates 
(black, flat-bottom, non-treated polystyrene) were purchased from VWR International 
(Radnor, PA, USA). Beetle luciferin, potassium salt was purchased from Promega 
(Madison, WI, UAS). GL261-Luc2 cells were a generous gift from Dr. Adrienne Scheck 
(Barrow Neurological Institute, Phoenix, AZ, USA). 
 Cell Culture 
GL261-luc2 expressing cells were maintained at 37°C and 5% CO2 on T25 tissue 
cultures flasks in DMEM supplemented with glucose, L-glutamine, 10% FBS and G-418 
antibiotic. Cells were detached with 0.25% trypsin-EDTA and counted using a cellometer 
mini (Nexcelom Bioscience, Lawrence, MA, USA) to obtain a final concentration of 
50,000 cells/2 µl for tumor inductions.  
 Nanoparticle Fabrication 
Nanoparticles were fabricated in endotoxin-free conditions. All glassware and 
centrifuge tubes were soaked overnight in a 1% w/v E-TOXA-Clean solution and 
glassware was baked at 250° C for 30 min. Nanoparticles were produced by single 
emulsion-solvent evaporation136 with slight modification. Briefly, 100 mg of PLGA and 
either 625 µg DiR or 8 mg CPT was dissolved in 1 ml of a 4:1 DCM: methanol mixture. 
The dissolved PLGA was added dropwise into 2 ml of 5% (w/v) PVA under vortexing and 
probe sonicated (Fisher Scientific Model 705 Sonic Dismembrator, Waltham, MA, USA) 
on ice in 3, 10-second bursts at 40% amplitude. The resulting emulsion was added to 50 
ml of 0.3% PVA, and this solution was stirred for 3 hours to evaporate solvent. 
Nanoparticles were collected by centrifugation for 20 min at 20,000 RCF and the 
resulting nanoparticle pellet was washed three times with DI water. The final 
nanoparticle pellet was resuspended in 1 ml endotoxin free water containing 25 mg 
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Trehalose, frozen, lyophilized for 48 hours, and stored at -80°C.  Blank nanoparticles 
were made by the same method as above without the addition of CPT or DiR. 
 Nanoparticle Sizing and Morphology 
To visualize surface morphology, lyophilized nanoparticles were mounted on 
double-sided carbon tape and sputter coated with gold for 30s at 40 mA. Samples were 
imaged on a SEM-XL30 Environmental FEG at 10 kV. Nanoparticle diameters were 
measured with ImageJ (v. 1.48, NIH) for a minimum of 200 nanoparticles taken from 5 
images. The hydrodynamic diameter and zeta potential of nanoparticles were 
determined at a concentration of 1mg/ml in water by dynamic light scattering (DLS) 
using a Delsa Nano C (Beckman Coulter, Pasadena, CA, USA). 
 Drug Loading 
Loading of CPT and DiR were determined by fluorescence. Nanoparticles were 
dissolved in DMSO to a concentration of 5 mg/ml. The nanoparticle solution (40μl) and 
DMSO (10μl) were pipetted into a black flat bottom 96 well plate and read on a 
fluorescent plate reader at the appropriate wavelengths (EX/EM 370/428 nm or 
750/780 nm, for CPT or DiR respectively). Three samples were read with technical 
triplicates averaged. Control curves were constructed by dissolving blank nanoparticles 
as described above and spiking with known amounts of drug or dye. 
 Controlled Release 
The method for measuring release of CPT from nanoparticles was adapted from a 
method described previously137. Nanoparticles (150 µg) with or without CPT were 
suspended in 2 mL of 1x PBS and incubated at 37°C on a shaker. At regular intervals 
(0.5, 2, 4, 6, 24 and 48 hours) samples were removed and centrifuged for 10 min at 
20,000 RCF. The nanoparticle pellet was discarded and 970 µL of the supernatant was 
removed and added to 30 µL of quantification fluid (DMSO: 1 N HCL: 10% SDS). Control 
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curves were constructed by spiking blank particle samples with known quantities of CPT 
for fluorescent readout by the method described above. Three samples were measured 
for each time point. 
 In Vivo Studies 
Nanoparticle brain distribution and tumor treatment efficacy were examined in 
vivo in a total of 64 C57BL/6 albino mice (Harlan Laboratories, Indianapolis, IN, USA). 
All procedures and animal care practices were performed in accordance with the Barrow 
Neurological Institute’s Institutional Animal Care and Use Committee. 
 Tumor Inductions 
Tumor induction protocol followed the methods established by Abdelwahab et al. 
with some modifications138. Mice were anesthetized with an intraperitoneal injection of 
ketamine (100 mg/Kg) and xylazine (10 mg/Kg) and mounted on a small animal 
stereotaxic instrument (Model 900, Kopf Instruments, Tujunga, CA, USA). Animal 
temperature was maintained using a circulating water heating pad placed beneath the 
frame. A sterile surgical field was obtained by three alternating passes of betadine 
solution and 70% isopropanol over the surgical site. An incision was made down the 
midline of the scalp to expose the skull and a burr hole was drilled to target the striatum 
(2mm lateral and 0.1mm posterior from bregma). A Hamilton syringe filled with 2 µL of 
the cell suspension (50k cells) was lowered to a depth of 3 mm and allowed to equilibrate 
with tissue for 1 min. The syringe was then withdrawn to a depth of 2.6 mm and the cells 
were infused over 2 min. The syringe was left in place for 1 min before it was removed to 
reduce back flow. The incision was closed using staples and a triple antibiotic ointment 
was applied to the scalp before placing the animal in a clean cage over a heating pad to 
recover. All animals received a single subcutaneous (SQ) injection of Buprenorphine (0.1 
mg/Kg). Ibuprofen was provided in drinking water for 1 week post-op to control pain. 
16 
 
 Tumor Growth 
Tumor growth was monitored every 3-4 days after tumor induction using the 
Xenogen IVIS Spectrum in vivo imaging system (Caliper Life Sciences, Hopkinton, MA, 
USA). Mice received a SQ injection of 150 mg Luciferin/kg and were imaged under 
anesthesia (2% isoflurane) at 25 minutes post injection. Regions of interest (ROIs) were 
drawn by hand to measure total flux (photons/s) using the IVIS Living Image software. 
 Tumor Localization of Particles 
25 tumor bearing C57BL/6 albino mice were used to measure accumulation of 
payload in tumor, peri-tumor and healthy brain tissue. Mice were imaged on the IVIS 
system one day prior to injection to determine tumor size. On days 4, 8, 12, 16 or 20, 
mice (n=5/ day) were injected with DiR-loaded nanoparticles (180 mg/kg) in 0.2mL by 
tail vein. 2 hours post-injection a blood sample was collected by cardiac puncture before 
mice were sacrificed and the brain removed, rinsed, and stored at -80°C. Frozen brains 
were sliced into 2 mm thick sections and imaged on a LI-COR Odyssey CLx (LI-COR 
Biosciences, Lincoln, NE, USA). After slices were imaged, 2 mm diameter punches were 
taken from tumor, peri-tumor and healthy (contralateral) striatal regions. The tissue 
punches were probe sonicated in 2.5% w/v water for 2, 10s bursts (40% amplitude). 
Tissue homogenates (50 μl) were mixed with DMSO (10 μl) in triplicate in a 96 well plate 
for fluorescent readout (EX/EM 750/780 nm). Control curves were constructed by 
processing punches from tumor bearing mice that did not receive nanoparticles (n=8 
mice) and spiking with known amounts of DiR. 
 Tumor Treatment Efficacy 
The antitumor efficacy of CPT-loaded PLGA nanoparticles was tested in 31 
C57BL/6 albino mice bearing orthotopic GL261-luc2 tumors. Animals were randomized 
into four treatment groups: saline, free CPT (10 mg/kg CPT), nanoparticle-encapsulated 
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CPT at a low dose (10 mg/kg CPT) (NP-10), and nanoparticle-encapsulated CPT at a high 
dose (20 mg/kg CPT) (NP-20). Free CPT was prepared for injection by dissolving CPT 
(50 mg/ml) in 1 M NaOH and titrating the pH to ~7 with PBS for a final solution of 1 
mg/ml CPT. Nanoparticles were prepared for injection by resuspension in sterile saline, 
and sonicated for 10 min to ensure no aggregates remained (Fisher Scientific Model 
FS30). Treatments were administered intravenously (IV) by tail vein injection on days 8, 
15 and 22 after tumor induction. Treatment efficacy was determined by tumor growth 
measured by IVIS, as described in 2.4.2, every 3-4 days following tumor induction and 
differences in mean survival time. Mice were monitored daily and euthanized upon > 
15% weight loss or signs of neurological symptoms. 
 Camptothecin Activity 
CPT activity in vivo was evaluated using immunohistochemistry (IHC). C57BL/6 
albino mice bearing orthotopic GL261-luc2 tumors received an injection of saline, free 
CPT or NP-20 and were euthanized 2 hours after treatment by cardiac perfusion with 
heparinized saline followed by 10% buffered formalin. Animal brains from each 
treatment group were harvested for tissue analysis. Formalin fixed brains were sliced 
into thick sections and embedded in paraffin. H & E staining and IHC staining were 
performed as described previously 139. Briefly, 5 μM thick sections from the tissue blocks 
were baked at 65°C for 1 hour, deparaffinized in three xylene washes, dehydrated in 
series graded ethanol, and rehydrated in water. Each slide was blocked in blocking buffer 
(3% Goat Serum, 1% BSA in PBS) and antigens were retrieved using a sodium citrate 
buffer (pH 6.5) for 20 minutes (BondMax autostainer; Vision Biosystems, Norwell, MA). 
IHC staining for γH2A.X (#9718, Cell Signaling Technology) and CD31 (ab28364, 
Abcam) was performed on serial sections from tissue blocks. Slides were incubated with 
primary antibodies, rinsed, and incubated with a HRP-conjugated secondary antibody 
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for 30 minutes followed by a DAB substrate. Lastly, sections were counterstained with 
hematoxylin and coverslipped.  
 Statistics 
All data analysis was performed in GraphPad Prism 5 software. Brain distribution 
data were evaluated by a 2-way ANOVA followed by Bonferroni post-test. Tumor growth 
curves were evaluated by fitting the growth data with a first-order exponential and 
comparing tumor doubling times using an ANOVA followed by Tukey’s multiple 
comparison test. Survival differences were evaluated from the Kaplan-Meier plot with 
the Mantel-Cox test. Differences were considered statistically significant for an alpha 
level of 0.05. 
2.4. Results 
 Nanoparticle Characterization 
SEM analysis confirmed that nanoparticles possessed a spherical shape with 
smooth surface morphology (Figure 2.1A, Figure 2.5). Nanoparticles sizes were relatively 
monodisperse (Figure 2.1A,C) with a mean particle diameter of 123 ± 31 and 119 ± 37 nm 
for CPT and DiR nanoparticles, respectively, as measured by SEM. DLS measurements 
yielded hydrodynamic diameters of 206 ± 32 and 204 ± 41 nm respectively and zeta 
potentials of -21.1 and -23.7 mV for CPT and DiR loaded nanoparticles, respectively 
(Figure 2.1C). Hydrophobic agents were effectively encapsulated in the NPs with drug 
loading efficiency of 9.6% for CPT and 0.5% for DiR. The CPT release profile of the 
particles was determined in vitro in PBS at 37°C (Figure 2.1B). Drug was initially 
released from nanoparticles in a burst of ~80% over 6 hours, and complete CPT release 
was observed within 24 hours.  
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 Tumor Localization 
NPs loaded with DiR, a hydrophobic, near infrared dye shown to release less than 
5% in 24 hours and commonly used to track NPs 140,141, were administered IV to evaluate 
the ability of NPs to deliver hydrophobic payload to an intracranial GL261-Luc2 tumors. 
Biopsy punches were taken from the tumor core, peri-tumor region below the tumor, and 
contralateral (healthy) hemisphere (Figure 2.2A). Nanoparticle payload accumulated in 
the tumor core at significantly higher concentrations compared to both healthy and peri-
tumor brain regions (p < 0.05) at day 12, 16 and 20 (Figure 2.2B). Payload delivery was 
positively correlated to tumor size for both tumor core and peri-tumor regions (p = 
0.0002 and 0.048, respectively) (Figure 2.2C).  
 Tumor Treatment Efficacy 
The tolerability and efficacy of CPT delivered in nanoparticle-encapsulated versus 
free form were evaluated in C57BL/6 albino mice bearing intracranial GL261-luc2 
tumors. Subjects received weekly injections of saline, free CPT, NP-10, or NP-20 for 3 
cycles. Subjects that received nanoparticle encapsulated CPT at both low and high dose 
experienced similar weight loss following treatment when compared to free CPT (Figure 
2.3A, shown with error bars in Figure 2.6). Tumor growth in saline-treated subjects was 
exponential, and no significant differences in tumor size were observed for mice treated 
with free CPT or NP-10 (Figure 2.3B). However, tumor growth was significantly slowed 
by treatment with NP-20. Additionally, NP-20 provided a significant survival benefit 
over the other treatment groups with a median survival of 36.5 days compared to 28, 32 
and 33.5 days for saline, free CPT and NP-10 respectively (Figure 2.3C). In a separate 
series of experiments, we established that blank nanoparticles did not alter survival 
when compared to saline treated controls (Figure 2.7). 
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 Camptothecin Activity 
CPT bioactivity was examined by γH2A.X staining in intracranial tumors of 
animals treated with saline, free CPT, and nanoparticle encapsulated CPT (Figure 2.4). 
Tumor sections taken from NP-20 treated mice showed an increase in staining intensity 
of γH2A.X compared to free CPT, with an average score of 3.0 as compared to 2.0, 
respectively (blinded scoring performed by board certified pathologist). These data 
support the hypothesis that encapsulation of CPT in nanoparticles allows for the delivery 
of greater amounts of CPT without adverse effects (Figure 2.4). To rule out the possibility 
that higher delivery of nanoparticle encapsulated CPT was due to higher vascularity of 
those particular subjects, we also examined CD31 staining intensity across different 
treatment groups 142. Each treatment group showed similar CD31 staining intensity. 
2.5. Discussion 
This study presents the use of CPT-loaded PLGA NPs for the systemic treatment 
of an orthotopic murine glioma. We achieved a loading of CPT in our nanoparticles of 
~10% by weight; this value is higher than our theoretical loading of 8%, indicating that 
more PLGA was lost than CPT during the nanoparticle fabrication process. Loss of PLGA 
during nanoparticle fabrication has been reported previously133, and our loading is 
consistent with the 5-25% loading reported by other groups encapsulating CPT in PLGA 
137,143. The average hydrated nanoparticle diameter measured by DLS (~200 nm) was 
larger than the diameter measured by SEM (~120 nm), which is expected, given that NPs 
will become hydrated in the aqueous environment required for DLS and that a fraction of 
nanoparticles will experience aggregation after resuspension. The zeta potential of our 
nanoparticles was approximately -21 mV, which is more negative than the purposed 
optimal range of -10 to +10 mV required to minimize nonspecific nanoparticle 
interactions and MPS cell clearance 51. NPs displayed CPT release kinetics typically 
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observed for PLGA nanoparticles, with an initial, rapid burst release followed by a period 
of slowed release and the majority of drug being released within several days. Drug was 
therefore effectively encapsulated for subsequent release in physiological environments.   
One advantage of using PLGA nanoparticles as drug delivery vehicles is that 
encapsulation of hydrophobic agents can improve their solubility and reduce toxicity. 
Toxicity remains a problem for CPT, which has a literature reported maximum tolerated 
dose (MTD) of 8-10 mg/Kg 62.  In our hands, injection of free CPT at a dose of 16 mg/Kg 
caused almost instant death (5-10 seconds), presumably due to its poor solubility. 
However, CPT was well-tolerated when encapsulated in PLGA NPs; no signs of acute 
drug toxicity were observed for doses of up to 30 mg/kg. We observed an MTD for 
PLGA-CPT NPs of 20 mg/Kg CPT, with higher doses resulting in weight loss after 
treatment (data not shown). This increase in CPT tolerability could be due to a 
combination of increased solubility and reduction of peak dose due to prolonged release 
of CPT from the particles. The extended release profile seen could also increase 
tolerability by allowing particles to deliver CPT to the tumor or be cleared before a 
majority of the CPT is released, thereby reducing CPT exposure to healthy cells. 
The difficulty of delivering drugs across the BBB makes the use of an intracranial 
tumor model critical for evaluating nanoparticle drug delivery; however, the most 
common GBM models (i.e. U87, U118, 9L) grow as bulky tumors, with well-defined 
borders and a highly disrupted BBB 134,135. The GL261 tumor model was chosen for this 
work for several reasons.  First, human GBM is characterized by diffuse and highly 
infiltrative growth, and it has been shown that GL261 tumors better recapitulate these 
characteristics with tumor cells invading into surrounding brain parenchyma where the 
BBB is still intact 144,145.  Additionally, GL261 cells share key genomic features with 
human GBM, including activated K-ras (mutant) and mutant p53, along with increased 
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activation of the PI3K/Akt pathway 134,146. Here we utilized a Luc2 transfected GL261 
model, which has been shown to have the same growth characteristics in vivo as the 
parent cell line, while enabling noninvasive tracking of tumor growth over time138,147. In 
future work, this model could be used to evaluate the delivery of molecularly targeted 
drugs that would not otherwise cross the BBB. 
It is well-established that nanoparticles can extravasate from peripheral 
circulation through leaky tumor vasculature into tumor core, a phenomenon termed the 
enhanced permeation and retention (EPR) effect; however, the optimal nanoparticle size 
for achieving the greatest EPR effect will depend on a number of factors including tumor 
type, location, and size of tumor. EPR data has been reported for nanoparticles ranging 
from 20-1000 nm in various tumor models 148–151. Previously 10 nm DSPE-PEG micelles 
have been shown to passively accumulate in intracranial GL261 tumors; however, to our 
knowledge, the nanoparticle size requirement for EPR-mediated delivery to intracranial 
GL261 tumors has not been evaluated. Thus, we were interested to study how 
nanoparticle payload was delivered selectively to tumor core versus periphery during 
tumor progression. Biopsy punches taken from the brains of tumor bearing mice 
administered PLGA-DiR NPs demonstrated that NPs preferentially accumulate in the 
tumor core, and this preferential delivery increased as a function of tumor size and with 
time post-tumor induction. These data suggest that effective delivery of hydrophobic 
payloads can be achieved even in late stages of growth in this intracranial model.  
The growth of intracranial GL261-Luc2 tumors was unaffected by treatment with 
free drug or with encapsulated drug at the MTD for free drug of 10mg/kg. However, 
CPT-loaded PLGA nanoparticles delivered systemically at a dose of 20 mg/Kg CPT 
slowed tumor growth and produced a significant increase in survival compared to all 
other treatments. CPT is a potent DNA damaging therapy and acts on cells by inhibiting 
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enzyme DNA topoisomerase I, which leads to generation of DNA double strand breaks 
(DSB), leading to apoptosis. DSB activates the DNA damage response (DDR) and 
produces accumulation of phosphorylated histone H2A.X (γH2A.X), a hallmark of DDR 
152. IHC analysis of γH2A.X validates that the slowed tumor growth and significant 
increase in survival of animals treated with NP-20 was due to the enhanced tolerability 
of nanoparticle encapsulated CPT, which enabled a higher total dose to be delivered. 
PLGA is both biocompatible and biodegradable, and has been used extensively 
for improving the action of chemotherapeutics 130–132, including in humans. For example, 
PLA-PEG nanoparticles encapsulating the chemotherapeutic drug doxorubicin are the 
subject of a phase II clinical trial in prostate cancer and non-small cell lung carcinoma 27. 
Other groups have encapsulated CPT within PLGA nanoparticles, and these formulations 
were effective when delivered directly to intracranial tumors, either by convection 
enhance delivery or from inside a hydrogel implant 19,133. The data presented here 
confirm that encapsulation of CPT can improve its activity. To our knowledge, this study 
is the first to report effective therapy of an intracranial tumor by systemic administration 
of CPT-loaded PLGA nanoparticles. Surface modification of nanoparticles – for example, 
attachment of poly (ethylene glycol) to improve circulation time, or ligands designed to 
facilitate transport of nanoparticles across the BBB could further improve payload 
delivery to the CNS 153. Enhancing delivery across an intact BBB to provide pan-CNS 
delivery of chemotherapies will improve drug access to invading cancer cells to improve 
tumor therapy.  
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2.6. Tables and Figures 
 
Figure 2.1:  Nanoparticle characterization. (A) Representative SEM image of CPT-loaded 
PLGA nanoparticles. (B) CPT was released from nanoparticles into buffer, with ~80% of 
total drug released after 6 hours. Points and error bars represent the mean ± SD, with 3 
samples measured for each time point. (C) CPT- and DiR-loaded nanoparticles had 
similar diameters, as measured by SEM and DLS, and similar surface charges. (Scale bar 
= 500 µm) 
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Figure 2.2:  NP payload delivery to orthotopic GL261 tumors.(A) DiR distribution 
(green) in a tumor bearing mouse brain captured on the LI-COR Oddyssey. Regions 
marked indicate example tissue punch locations used for tumor (1), peri-tumor (2) and 
healthy brain (3). (B) DiR accumulation was significantly higher in the tumor compared 
to peri-tumor or healthy brain regions, 12, 16 and 20 days post tumor implantation 
(p=0.01) Bars indicate mean ±SD (n=5 mice/day). (C) The amount of DiR/ g tissue, 
quantified by fluorescence for each region, positively correlated with tumor size for both 
tumor core and peri-tumor regions (p=0.002 and 0.048 respectively). 
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Figure 2.3: Treatment efficacy studies. (A) Mice receiving CPT either freely or in a NP 
showed similar weight fluctuations over the course of treatments. Saline treated mice 
weight remained steady until the tumor burden became too great. (B) Tumor burden 
monitored by IVIS showed NP-20 significantly slowed tumor growth (p=0.01) and 
provided a significant survival benefit (C & D) compared to all other treatments. Error 
bars indicate ± SD. 
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Figure 2.4: Camptothecin bioactivity. Left panel shows H & E staining of the tumor cells 
in saline, free CPT and nanoparticle encapsulated CPT (20 mg/Kg) treated animals. 
Center panel shows γH2A.X staining on the serial section, and demonstrates very high 
γH2A.X staining for animals treated with nanoparticle encapsulated CPT (20 mg/Kg) 
(IHC Score =3) as compared to saline (IHC score = 1-2) and free CPT (IHC score = 2) 
treated animals. Right panel shows the CD31 staining on the serial section, and 
demonstrates similar staining intensity in all the treatment group. Positive staining in 
each section is indicated by black arrow. All the images are taken at 20X magnification 
(scale bar in top left panel = 100 µm). (n=3 mice/treatment)        
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Figure 2.5: Representative SEM image of DiR-loaded PLGA nanoparticles. (Scale bar = 
500 µm) 
 
Figure 2.6: Treatment tolerability. Mice receiving CPT either freely or in a NP showed 
similar weight fluctuations over the course of treatments. Saline treated mice weight 
remained steady until the tumor burden became too great. Error bars indicate ± SD. 
(n=7-8 mice/treatment) 
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Figure 2.7: Effects of blank NPs on GL2621 tumor growth. Kaplan-Meier survival curves 
for the treatment of intracranial GL261-Luc2 tumors. Either saline or blank NPs (no 
drug) were delivered intravenously on days 7, 14 and 21. No significant survival 
differences were observed with a median survival of 21 days versus 19 days for saline and 
blank NPs respectively (Mantel-Cox test, p= 0.8229). 
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Evaluating the Transport and Fate of Nanoparticles within the 
Cerebrospinal Fluid after Intrathecal Administration 
3.1. Abstract 
Effective treatment of neurological diseases remains a significant challenge to our 
society, due largely to the inability of systemic therapeutics to reach the central nervous 
system. The circulation of cerebrospinal fluid (CSF) around the entire brain and spinal 
cord makes it an attractive delivery medium to avoid systemic barriers; however, most 
therapies administered intrathecally have failed due to inadequate distribution and rapid 
clearance. Despite extensive use of nanoparticle (NP) drug carriers to prolong circulation 
and alter distribution of systemic therapies, the potential use of NPs for intrathecal (IT) 
administration remains poorly characterized. Here, we tracked the distribution and 
retention of 100 nm NPs after IT administration to evaluate their potential as a drug 
delivery system for IT therapies. We found NPs were well tolerated and rapidly 
distributed along the entire neuraxis within 2 hours by the convective forces of the CSF 
after IT administration. A significant population of NPs was retained within the CSF 
space for over 3 weeks, with a majority of clearance occurring through the cribriform 
plate. Comparison of NP localization around the brain and spinal cord showed 
distinctive distribution patterns due their unique anatomies and geometries. Taken in 
sum, these studies demonstrate the ability of 100 nm NP to achieve wide spread delivery 
along the neuraxis and highlight their potential for IT drug delivery applications. 
3.2. Introduction 
Achieving effective drug delivery to the central nervous system (CNS) remains 
one of the greatest challenges in treating CNS diseases. Systemically administered 
therapies are largely ineffective due to the presence of the blood-brain and blood spinal 
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cord barriers, which exclude an estimated 98% of small molecules and all large 
molecules154. Active agents capable of crossing these barriers still typically require large 
doses to achieve adequate CNS concentrations, often resulting in severe off-target effects 
in peripheral organs and tissues.  
To circumvent these systemic barriers, administration of active agents directly 
into the cerebrospinal fluid (CSF) surrounding the brain and spinal cord has gained 
renewed attention as a potential delivery route. Intrathecal (IT) administration is 
especially appealing due to its ability to achieve high concentrations of drug in the CSF at 
a fraction of the dose necessary by systemic routes108,109. However, its translation into 
patients has presented several challenges, and most therapies have failed clinically due 
to poor pharmacokinetics and toxicity 90,155–159. While hydrophilic compounds are 
typically capable of distributing through the CSF, they tend to suffer from rapid 
clearance with the continuous turnover of CSF and require frequent dosing91,118,121,124,160. 
The high propensity of hydrophobic/lipophilic compounds to enter cells and bind to 
extracellular matrix proteins restricts their distribution close to the site of injection, 
which limits the ability of locally administered agents to treat diseases affecting non-
focal regions of the CNS123–125,161.  
Encapsulation of therapeutics within polymeric or liposomal nanoparticles (NPs) 
has been utilized extensively to overcome similar pharmacokinetic limitations of 
systemically administered agents1,14,15,132,162,163, yet NP-based drug delivery approaches 
have received minimal attention for improving intrathecal therapies. The versatility of 
NP properties allows for a wide range of compounds to be effectively encapsulated and 
then released over prolonged periods of time162. Thus, if NPs could be designed to 
effectively move through CSF filled compartments in the CNS, it would be possible to 
further develop them to deliver drugs across CSF-exposed tissues. Here, we evaluated 
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the ability of NPs to distribute throughout the CNS via the CSF after intracisternal 
administration in healthy mice. To understand the broad kinetics of NP movement along 
the neuraxis, we tracked the distribution FluoSpheres (fluorescent polystyrene beads) in 
vivo using an IVIS imaging system. We also used confocal microscopy on ex vivo tissue 
slices to examine NP fate with respect to tissue structures to identify potential barriers 
and opportunities for NP drug delivery by IT administration. These studies are expected 
to have broad implications on the use and design of NPs for CSF delivery across CNS 
diseases.  
3.3. Materials and Methods 
 Materials 
100 nm carboxylate-modified FluoSpheresTM (red fluorescent, Ex/Em 
580/605nm), 10 µm FluoSpheres (green fluorescent, Ex/Em 468/508nm) and 20x 
Borate Buffer were purchased from ThermoFisher Scientific (Waltham, MA USA). All 
water was endotoxin-free (<0.0050 EU/ml), obtained from G-Biosciences (St. Louis, 
MO, USA). Poly(ethylene glycol)-amine (mPEG-Amine, 2 kDa MW) was purchased from 
Creative PEGWorks (Chapel Hill, NC USA). All other chemicals or reagents were 
purchased from Sigma-Aldrich (St. Louis, MO USA) unless specified. 
 FluoSphere PEGylation and Characterization 
Carboxylate-modified FluoSphereTM (FS, 100 nm) NPs were covalently modified 
with mPEG-Amine (2k Da MW) by carboiimide chemistry as previously described by 
Nance et al.38. FS in 500 µl aliquots were washed to remove sodium azide using 0.5 ml 
Amicon-Ultra centrifugation filters (10k MWCO). Retained FS were resuspended with 
water bath sonication in 2 ml endotoxin-free water. mPEG-amine (5x molar excess) was 
added to the FS and allowed to stir for 15 min. Next, 6.5 mg N-Hydroxysuccinimide 
(NHS) dissolved in 6 ml borate buffer (200 mM, pH8) was added to the stirring FS 
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solution, followed by 15.4 mg 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC). 
The reaction was left stirring for 3 hrs at room temperature before quenching with excess 
glycine (100 mM) for 30 min. Unreacted PEG, EDC, NHS and glycine were removed by 
dialysis (100k MWCO) against 4 L DI water for 24 hours. FS were collected, further 
washed by centrifugation using 15ml Amicon-Ultra centrifugation filters (100k MWCO), 
and resuspended to 20 mg/ml in 1x PBS for storage at 4°C until use.  
 Size and Zeta Potential 
FS size and zeta potential was measured in 1 mM KCl before and after PEGylation 
using the NanoBrook 90Plus Zeta (Brookhaven Instruments, Holtsville, NY USA). Each 
sample was measured 10 times and averaged across 3 technical repeats. 
 In Vivo Studies 
All procedures and animal care practices were performed in accordance with the 
Barrow Neurological Institute’s Institutional Animal Care and Use Committee. Healthy 
C57 albino mice (Charles River) were used for the following in vivo experiments. 
 FluoSphere Administration 
FS were administered directly into the CSF through the cisterna magna. Mice 
were anesthetized with ketamine/xylazine (100/10 mg/kg) and mounted in a stereotaxic 
frame (Kopf Instruments, Tujunga, CA, USA) on top of an infrared heating pad. The 
head was shaved and sterilized with three alternating passes of betadine and ethanol. A 1 
cm incision was made over the cerebellum and neck before removing the bite bar and 
dropping the head to a 60° angle with the body. The muscle over the neck was carefully 
retracted to expose the dura covering the cisterna magna. A Hamilton syringe (29 gauge 
needle, 30° beveled tip) containing 2 µl FS was inserted through the membrane to a 
depth of 1.5 mm. The syringe was then retracted to 1 mm and allowed to equilibrate for 1 
min. The FS were injected over 1 min, and the needle was left in place for an additional 2 
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min before removing. The incision was closed with staples and treated with a topical 
antibiotic. All animals received a subcutaneous (SQ) injection of Buprenorphine SR (1 
mg/kg) prior to surgery, and ibuprofen was provided in their water for 1 week to control 
pain.  
 In Vivo FluoSphere Tracking 
Macroscopic FS fluorescent distribution and clearance kinetics were first 
examined using a Xenogen IVIS Spectrum In Vivo Imaging System. Prior to FS injection, 
clippers and Nair were used to remove the fur along head and back. A pre-injection 
image was captured to control for background autofluorescence. FS were administered 
as described above (3.3.5), except tissue glue was used instead of staples to reduce signal 
attenuation. At 5 min, 2, 6, 24 and 48 hours after injection, the mice were imaged in the 
IVIS (Filters: Ex 570/Em 620) under 2% isoflurane. Using the Living Image Software, a 
line profile was drawn along the length of the neuraxis to quantify FS intensity at each 
pixel. Background signal measured from the pre-injection image was subtracted within 
subject from each time point. FS intensity was normalized within each subject to the max 
intensity at 5 min. 
 Ex Vivo Neuraxis Collection 
Mice were sacrificed at 2, 6, 24, 48 hrs, 1 and 3 wks post FS administration, to 
examine 100 nm FS fate at the cellular level. Mice were perfused through the heart with 
15 ml heparinized PBS (1000U/ml) followed by 10 ml 4% paraformaldehyde (PFA). To 
preserve the integrity of the leptomeninges, the entire neuraxis, from nasal sinuses to 
sacral spinal region, was isolated with the aid of dissection scissors, removing the 
majority of muscle and skin but leaving the bone intact. The neuraxis was post-fixed in 
4% PFA for an additional 48 hrs. The bone was decalcified in a 4% HCl and 4% Formic 
Acid v/v solution, replaced daily, for 5 days. This procedure enabled cryosectioning of 
35 
 
the neuraxis without removing the bone. After cryoprotection in a 30% (w/v) sucrose 
solution for 48 hrs, the brain and spinal cord were cut at the C1 vertebrae to enable 
separate processing. We validated that decalcification does not produce substantial loss 
or redistribution of fluorescence signal by IVIS imaging two complete neuroaxis before 
and after decalcification. Although the fluorescence signal was observed to increase 
slightly after decalcification, presumably because the reduction of signal attenuation by 
bone, the relative signal distribution along the neuraxis remained consistent. 
 Brain and Spinal Column Processing 
The spinal column was dissected into a total of eight 5 mm sections starting at C1. 
These 8 sections were placed caudal side down in a disposable cryomold, embedded in 
Tissue-Tek OCT and frozen at -80° C. 20 µm slices were cut on a Leica cryostat, resulting 
in 8 coronal spinal sections of known distances along the spinal column. For the brain, a 
single hemisphere from each sample was embedded in OCT and frozen at -80° C before 
slicing into 20 µm sections. The slides were washed 3x with 1x PBS to remove the OCT, 
counterstained with Vectashield plus DAPI mounting medium, and cover slipped. A 
Zeiss LSM confocal microscope was used for all imaging. Brain sections and spinal 
sections were imaged for FS (Ex 560/ Em 605 nm) using a 10x objective, and T-PMT was 
used to provide a contrast image of the anatomy. Laser intensities and gain were 
maintained across samples and time points. For quantification of the spinal cord 
distribution, an average background pixel intensity (based on non-injected controls) was 
subtracted from each image and the FS intensity was measured by ImageJ (v1.47, NIH).  
 Statistical Testing 
All statistical tests were performed using the GraphPad Prism 5 software. 
Comparisons of AUC over time were made with a 1-way ANOVA with Bonferroni 
Multiple Comparisons test.  Statistical significance is reported for p < 0.05.  
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3.4. Results 
 FluoSphere PEGylation 
Successful PEGylation of FS via EDC chemistry was confirmed by DLS, via 
observation of the expected increase in average diameter and shift in zeta potential 
towards a more neutral charge. After PEGylation, the 100 nm FS diameter increased to 
122 ± 8.17 nm and the zeta potential shifted from -45 ± 5.4 to -14 ± 2.2 mV. 
 In Vivo FluoSphere Tracking 
FS distribution along the neuraxis was monitored in intact mice over the course 
of 2 days using an IVIS Spectrum imaging system. FS were administered directly into the 
CSF through the cisterna magna, and the mice were imaged 5 min, 2, 6, 24 and 48 hours 
post-injection. It is important to note that due to the limitations of fluorescence 
penetration, IVIS could only reliably detect the FS along a short segment of the spinal 
column, in the middle of the back, where the signal was not obstructed by the 
musculature of the shoulders and hind legs. Beginning at the first time point measured 
(5 min post injection), the FS signal was focused at the injection site with no detectable 
signal along the spinal cord (Figure 3.1A). By 2 hrs, the FS signal spread over the entire 
brain region and was detected along the spinal cord, although the strongest signal 
remained focused at the injection site. From 2 to 48 hours post-injection, FS signal 
around the brain continued to move away from the injection site towards the olfactory 
bulb. The brain AUC significantly decreased from 6.6 at 2 hrs to 2.7 AU*hrs by 48 hrs 
(p=.0098, Figure 1C) with the greatest clearance observed from 2 to 6 hrs (6.6 to 4.8). 
Although there was a modest decrease in FS AUC along the spinal cord from 2 to 6 hrs 
(1.9 to 0.86), the signal AUC increased back to 1.2 by 48 hours. Overall, there were no 
significant changes to the total FS delivery along the spinal cord.   
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 Ex Vivo Spinal Column Distribution 
Transverse cryosections, taken from known distances along the spinal column, 
were imaged by confocal microscopy to visualize FS distribution around and along the 
spinal cord. Although it is difficult to visualize the boundary between the pia matter and 
the parenchyma, our initial observations did not suggest any significant FS penetration 
into the spinal parenchyma from the CSF. In a subset of animals, we removed the bone 
and meninges prior to imaging. Removal of the meninges resulted in a loss of nearly all 
detectable FS signal, providing some evidence that the FS are almost completely retained 
within or at least very strongly associated with the meninges. 100 nm FS were observed 
along the entire length of the spinal cord within 2 hours and encompassed the entire 
circumference of the spinal cord, including within the meninges of exiting nerve roots 
(Figure 3.2 and 3.3). There was a slight tendency at all time points to observe a greater 
concentration of FS along the ventral spinal cord surface. Interestingly, we consistently 
observed a small population of FS within the central canal at each time point, specifically 
in cervical and thoracic spinal sections. At 3 weeks after injection, the FS were still 
readily detected along the entire length of the spinal column; although they appeared as 
more punctate foci compared to earlier time points. To test if the rapid distribution of 
the FS to the sacral spinal cord was size dependent, we examined the ability of 10 µm 
non-PEGylated FluoSpheres (MFS) to transverse the leptomeningeal space. Surprisingly, 
the MFS could be found in the sacral region within 2 hours, albeit very infrequently (3 
total in 54 slices observed). We also did not find more than 2 MPS per tissue slice past 10 
mm down the spinal column.  
Quantification of FS intensity by ImageJ revealed a gradual exponential decay in 
fluorescent signal moving caudal from the injection site towards the sacral spinal section 
(Figure 3.4). Overall, the tissue slice quantification agreed with the trends seen in the 
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IVIS tracking. For the first 48 hours and even out to 1 week, the total FS delivery (AUC) 
to the spinal column did not significantly change (Figure 3.3H). We did observe a similar 
decrease in AUC from 2 to 6 hours (3.4E9 to 2.4E9), followed by a slight increase in 
delivery from 24 to 48 hours (2.7E9 to 3.0E9). Interestingly, the FS concentration along 
the spinal cord continued to trend upwards from 48 hours to 1 week (3.0E9 to 3.8E9) 
and was significantly higher at 3 weeks post-injection (5.1E9) compared to 6, 24 and 48 
hours (p<0.05).  
 Ex Vivo Brain Distribution 
To visualize the anterior/posterior distribution of FS around the complex 
geometries of the brain, the brain was sliced in sagittal sections (Figure 3.6). Consistent 
with our observations along the spinal cord, we found minimal evidence of FS 
penetration across the pia mater into the brain parenchyma. In general, FS distributed 
throughout the entire meningeal network on the surface of the brain. FS were observed 
to follow the meninges into the sulci of the cerebellum and along the trigeminal nerve. 
FS delivery was consistently concentrated along the ventral side of the brain compared to 
the dorsal side, and FS signal was especially sparse along the dorsal prefrontal cortex 
region at all time points. To test whether the ventral preference was an artifact of the 
mouse lying in the prone position after injection, we injected 3 additional mice but kept 
them on their back for 2 hours post-injection prior to perfusion. Interestingly, recovery 
position did not produce any obvious qualitative changes to the FS distribution, and 
delivery to the prefrontal cortex region remained sparse (Figure 3.6). In all mice, we 
observed the greatest concentrations of FS within concave structures around the brain, 
specifically the supracerebellar cistern between the cortex and cerebellum on the dorsal 
side of the brain and the pituitary recess anterior of the pons on the ventral side of the 
brain 
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 Peripheral Clearance 
We found evidence of FS clearance across the cribriform plate into the nasal 
sinuses (Figure 3.5) at all time points. To test whether cisternally administered FS were 
cleared into peripheral compartments, we examined the liver and spleen with confocal 
microscopy. There was no observable FS signal above background in the liver at any of 
the time points (data not shown). FS were detectable within the spleen at all time points, 
although the greatest concentration of FS was seen at 2 hours after injection (Figure 3.7). 
Anatomically, FS appeared to be consolidated around the white pulps of the spleen. 
3.5. Discussion 
The presence of CSF around the entire brain and spinal cord and through the 
parenchymal interstitial spaces makes it an attractive delivery medium for neurological 
therapies. CSF is produced by the choroid plexus, after which it moves through the 
ventricles into the cisterna magna, where it distributes down the spinal cord and around 
the brain through the leptomeningeal space 93,164. Although the overall magnitude of a 
bulk or net directional flow of CSF is debated, it is generally accepted that CSF moves in 
a pulsatile fashion due to the rhythmic forces generated by the cardiac and respiratory 
cycles 96–98,110. The ebb and flow of CSF along the neuraxis is predicted to further interact 
with the complex network of trabeculae and exiting nerve roots within the SAS to 
generate local vortexes of CSF mixing. Between the convective forces of CSF flow and the 
local areas of CSF mixing, it would be expected that drugs administered into the CSF 
would rapidly disperse along the neuraxis. However, most therapies of interest for 
neurological disease are believed to be unable to distribute through the CSF, and the use 
of intrathecal administration in the clinic has been mainly limited to analgesics. SPECT 
studies by Wolf et al suggest the limited distribution is due to the biophysical properties 
of the drugs, with the propensity of the therapy to bind cellular and ECM components 
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dictating the ability of the molecule to move away from the injection site 124.While this is 
advantageous for the translation of highly lipophilic analgesics for intrathecal therapy, 
where local delivery is a necessity to avoid possible detrimental respiratory side effects, 
many therapies for CNS diseases are also lipophilic but require therapeutic delivery 
throughout the neuraxis. The objective of our studies was to evaluate whether the 
biophysical properties of 100 nm PEGylated nanoparticles allow them to distribute 
through the CSF to achieve uniform delivery along the entire neuraxis after intracisternal 
administration. 
Nanoparticles have been administered intrathecally previously, but most studies 
did not track nanoparticle distribution following administration123,165–167  or only showed 
efficacy in providing local sustained delivery for the treatment of spinal cord injury84–86. 
Our studies show 100 nm FS administered through the cisterna magna were well 
tolerated and distribute through the meninges along the entire neuraxis, including into 
the sulci of the brain and along nerve bundles (trigeminal, optic and exiting spinal nerve 
roots). Distribution of the 100 nm FS to the sacral portion of the spinal column within 2 
hours post administration is too rapid for Fickian diffusion alone, supporting the 
hypothesis nanoparticles are carried convectively by CSF flow. Movement of the FS in all 
directions from the cisterna magna is supportive of CSF mixing driving solute 
movement, rather than strictly directional laminar CSF flow96,97,110,113.  
CSF mixing has been proposed to be especially important along the spinal cord, 
where multiple studies predict the overall CSF movement to be nearly completely 
ossillatory98,168,169. The magnitude of these oscillations is expected to decrease caudally 
along the spinal column. We observed here that while FS were able to access even distal 
regions of the spinal cord, a gradient exists in the rostral-caudal direction. This gradient 
could represent an equilibrium established by the decreasing oscillatory forces produced. 
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The more punctate clustering of the FS signal at 3 week does suggest a possible 
contribution from some FS becoming trapped by the microanatomy of the SAS as they 
move down the spinal column. Based on prior works by Wolf et al. and Papisov et al., the 
observed moderate exponential FS gradient along the spinal column is consistent with 
the distribution of hydrophilic, low-binding small molecules injected intracisternally or 
intraventricularly124,160. Whereas, if the FS were experiencing significant tissue binding, 
as would be typically observed for hydrophobic/lipophilic small molecules, we would 
expect to see a significantly faster decay in signal124,160. When the same hydrophilic 
molecules were administered by lumbar injection, especially with the addition of a saline 
flush, distribution along the spinal cord increased and was more uniform while 
minimally reducing FS delivery to the brain SAS. Due to the compliance of the cisterna 
magna membrane and lack thereof along the spinal column, the cisterna magna is 
thought to accept the excess volume administered at the lumbar region, driving solute 
movement towards the cranial SAS. Thus, we expect a similar approach could be applied 
to the nanoparticle injection to further improve the uniformity of delivery across the 
neuraxis.  
Distribution of FS around the brain was considerably more heterogeneous than 
the spinal cord. While no obvious preference for either hemisphere was observed, both 
sagittal and coronal brain sections showed a strong preference for FS movement along 
the ventral side of the brain. This asymmetrical distribution does not appear to be 
dependent on solute molecular weight: we observed this for 100nm FS, as it was 
similarly observed for both a small molecule (99mTc-DMSA, ~500 Da) and a protein 
(idursulfase, 76 kDa) following lumbar injection124,160. We also confirmed the ventral 
distribution was not an artifact of animal position following injection, suggesting there 
might be inherent differences in net CSF movement/clearance around the dorsal and 
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ventral brain. To our knowledge, this has not been directly measured. FS are clearly 
capable of redistributing in all directions following their injection into the cisterna 
magna. A relatively high FS concentration is observed in the supracerebellar cistern at all 
time points, whereas a relatively small population of FS appear to move past the cistern 
towards the olfactory bulb, with a fewer but significant number of FS observed in the 
olfactory bulb. We saw a similarly pronounced concentration of FS within the pituitary 
recess on the ventral brain, except significantly more FS moved rostrally beyond the 
recess. We expect the increased deposition of FS within concave structures around the 
brain is a result of strong areas of local CSF mixing, similar to the phenomenon of 
platelet deposition within an aneurysm170,171. The different orientations and potential 
differences in trabeculae densities between the supracerebellar cistern and the pituitary 
recess may also contribute to the stark differences in the movement of FS past these 
regions. Taken in sum, our data demonstrate that 100nm FS are capable of distributing 
throughout the entire leptomeninges of the brain. However, there were significant 
differences, consistent across time points, observed in FS distribution to specific regions 
around the brain. We cannot say whether the distinct patterns of delivery observed for 
100nm FS could be generalized to other substances injected into the CSF, such as small 
molecules, proteins, or gene therapies. However, the kinds of differences observed for FS 
were of an order of magnitude that would be expected to influence the activity of 
therapeutic molecules. These results therefore highlight the need for additional work to 
further elucidate how microanatomy of the leptomeninges and regional CSF dynamics 
influence the distribution and activity of delivered agents. 
 In addition to inadequate distribution, many compounds injected into the 
CSF also suffer from short half-lives, typically on the order of a few hours121. This rapid 
clearance gives minimal time for the drug to distribute along the neuraxis to its target 
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before being cleared. Here, we found 100 nm FS, which are non-degradable, remained 
distributed throughout the neuraxis for over 3 weeks. This long residence time may be 
useful from a drug delivery perspective, allowing ample time for a drug carrier to 
distribute to target regions, interact with cells, and release its payload over days to 
weeks. Considering the continuous turnover of CSF multiple times a day (4x/day in 
human, 12x/day in mice)95,99, the prolonged retention of our 100 nm FS was unexpected. 
It is likely that the long residence time is a function of FS size. CSF clearance is proposed 
to occur through multiple routes, including, 1, direct to blood transfer through arachnoid 
villi, 2, movement across the cribriform plate into the nasal mucosa, and, 3, perineural 
transport along both cranial and spinal nerve roots. The significance of each of these 
routes across species is often debated 94,110,172–174. Both our IVIS and confocal data suggest 
the majority of FS clearance occurs from the brain compartment with minimal clearance 
along the spinal cord. In agreement with prior works in rodents, we see strong evidence 
for CSF movement across the cribriform plate into the nasal mucosa as a major clearance 
route for FS at all time points. Although we do observe some FS being cleared to the 
spleen, suggesting FS are accessing the blood, we are unable to discern whether these 
come from FS that leaked into the muscle at the injection site or FS cleared from CSF 
into blood. One possible explanation for the lack of FS along the dorsal brain is due to 
clearance into venous circulation through arachnoid villi along the Superior Sagittal 
Sinus (SSS); however, recent works suggest direct CSF to blood clearance is minimal in 
mice172,173 and we failed to observe direct interactions of the FS within the SSS in coronal 
sections. We consistently observed FS interactions with exiting nerve roots along the 
spinal cord but were not able to follow them into the periphery. While our data suggests 
minimal change in FS concentration along the spinal cord over time, FS exiting into the 
periphery combined with FS in the cisterna magna acting as a source may contribute to 
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the observed lack of clearance and the concentration gradient along the spinal column. 
Future studies using whole body imaging would be necessary to fully understand the 
contribution of each of these clearance routes in the context of nanoparticle distribution.  
Nanoparticle size is one of the most important biophysical parameters governing 
nanoparticle fate following delivery by most routes of administration, including 
intravenous30,32, oral34,175, intranasal35,36, or convection enhanced delivery37,38. Due to the 
small pores formed by the heterogeneous distribution of arachnoid trabeculae within the 
leptomeningeal space176,177, we expected that large nanoparticles would not be capable of 
traversing the subarachnoid space to reach CNS tissues distant from the injections site. 
Although it’s known a small population of DepoCyt, a 10 µm multilamellar liposome, 
reaches the lumbar region within a day following intraventricular administration in 
humans, we expected the smaller mouse anatomy would be more restrictive to 
microparticle movement. In contrast to this expectation, we found 10 µm non-PEGylated 
FS were capable of navigating the SAS to the sacral spinal cord within 2 hours of IC 
administration in mice. However most distal slices contained no FS and those that did 
never contained more than 1 FS/slice. While these microparticle systems can help 
overcome the issue of rapid drug clearance through prolonged drug release, the minimal 
number of FS in distal regions means these systems must still inevitably rely on the drug 
to diffuse or be carried away from the particle to its target. Smaller nanoparticle systems, 
such as the 100 nm NPs used here, should not need to rely on drug movement due to 
their more uniform and complete distribution. In addition, their small size means they 
can be easily taken up into cells, allowing for opportunities to potentially increase 
delivery to specific cells or regions through targeting. As anticipated, the minimal 
penetration of 100 nm nanoparticles across the pia mater or diffusion along perivascular 
routes in the parenchyma, limiting their use for applications requiring delivery to deep 
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CNS regions. Although nanoparticles as large as 100 nm can maneuver through brain 
perivascular spaces under convection enhanced delivery38, sub-50 nm and ideally >20 
nm nanoparticles are necessary to achieve significant penetration from the SAS into the 
brain178,179. The retention of 100 nm FS within the leptomeningeal space does support 
future work examining their potential for overcoming the pharmacokinetic limitations of 
therapies for treating diseases of the meninges, including meningitis, meningiomas and 
leptomeningeal metastasis from solid tumors. Ultimately, our data provide the first 
direct evidence that 100nm NPs are capable of distributing rapidly through the 
leptomeninges of the brain and spinal cord following cisternal administration in healthy 
mice, which opens new therapeutic opportunities to consider delivery of drug loaded NPs 
via this administration route. 
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3.6. Tables and Figures 
 
Figure 3.1: IVIS tracking of FS distribution after IC administration in intact healthy mice. 
(A) Representative images showing the spread of FS away from the cisterna magna over 
time. FS were detectable along the spinal cord by 2 hours but only along the mid of the 
back unobstructed by the extra muscle of the fore and hind legs. (B) Graph of FS 
intensity along the neuraxis quantified using a line profile from nose to tail. The FS 
signal was normalized within each mouse to the max intensity at 5 min and averaged 
across mice (n=4 mice). (C) AUCs of the brain signal (-20 to 10 mm) and spinal signal 
(10 to 40 mm) showed significant clearance of FS from the brain region from 2 to 48 
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hours (p<0.05, 1-way ANOVA), while the FS intensity along the spinal cord did not 
significantly change over the 48 hours. Mean+ SD shown in B to help keep lines visible. 
AUC points show mean ± SD.  
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Figure 3.2: Representative confocal images of FS distribution at along the spinal cord at 
2 hours and 3 weeks. FS (red) distributed to the sacral regions of the spinal column 
within 2 hours and remained for over 3 weeks. Even at later time points, the FS appeared 
to be confined to meninges with minimal evidence for parenchymal penetration. The 
location of the slice along the spinal column is given in the lower left. Equivalent linear 
adjustments were made to the FS signal in each image to enable better visualization. Cell 
nuclei (DAPI) is shown in blue.  
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Figure 3.3: Representative confocal images of FS distribution at different locations along 
the spinal column over time. FS delivery along the spinal column appeared to be 
consistent over time. Equivalent linear adjustments were made to the FS signal in each 
image to enable better visualization. Cell nuclei (DAPI) is shown in blue.  
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Figure 3.4: Quantification of FS intensity along the spinal column following IC injection. 
(A-F) Scatter plots for each time point showing the distribution of measured FS intensity 
and the resulting exponential curve fit of all the data points (solid line) with the 95% 
confidence interval (dashed line). Each point represents the measured intensity within a 
given tissue slice, and within each graph, the same color and shape represent tissue slices 
from the same animal. (G) Single graph showing the shape of the FS intensity curve fits 
remained constant across time points. (H) AUC of the curve fits for individual mice at 
each time point shows FS delivery to the spinal cord trended upwards over time and was 
significantly higher at 3 weeks compared to 6, 24 and 48 hours (p<0.05, 1-way ANOVA 
with Bonferroni’s Multiple Comparison Test). Mean ± SD shown.  
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Figure 3.5: Representative confocal images of FS distribution around the brain. FS (red) 
were distributed around the entire brain and could be seen following the meninges into 
the sulci of the cerebellum (arrows).  There was a strong preference for ventral 
distribution and consistently high delivery to the supracerebellar cistern (C) and 
pituitary recess (P). Clearance of FS across the cribriform plate into the nasal mucosa (N) 
was seen at all time points. Qualitatively, a general decrease in total FS intensity was 
observed over time. Linear corrections were applied equally across images to better show 
FS distribution and the gross anatomy of the brain. 
 
Figure 3.6: Mouse position does not affect FS distribution around the brain. Brain image 
from a mouse allowed to recover on its back during the 2 hours after injection. FS (red) 
distribution was still favored towards the ventral brain and minimal delivery was 
observed to the prefrontal cortex regions of the SAS (arrow).  
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Figure 3.7: Representative confocal image of FS distribution to the spleen at 2 hours. FS 
(red) appeared to be localized around the white pulp. Cell nuclei (DAPI) shown in blue. 
Scale bar = 100 µm  
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Evaluation of Nanoparticle Delivery to Leptomeningeal Metastasis by 
Intrathecal Administration and the Effects of CGKRK-targeting on 
Nanoparticle Fate 
4.1. Abstract 
Medulloblastoma (MB) arises in the cerebellum and is the most common 
pediatric brain tumor. While there are some effective treatment options for the primary 
tumor, patients exhibiting leptomeningeal metastasis (LM) have a significantly worse 
prognosis. LM involves the spread of the tumor to the cerebrospinal fluid (CSF) and 
infiltration into the meninges surrounding the brain and spinal cord. Intrathecal (IT) 
injection of chemotherapy directly into the CSF is an appealing approach to avoid 
systemic barriers to treatment, but poor distribution and rapid clearance of IT therapies 
has limited efficacy of this approach. We have previously shown that IT administered 
nanoparticles (NPs) exhibit prolonged wide spread distribution along the subarachnoid 
space of the neuraxis in healthy mice, but their potential for delivery to LM remains 
unexplored. Modification of NP with targeting ligands has been shown to be a potential 
strategy to increase or prolong NP localization with target cells after intravenous 
administration, which opens the possibility that this approach could be useful for 
enhancing NP localization with target cells when NPs are administered IT. Thus, the goal 
of this work was to evaluate the ability of IT administered NPs to localize with LM 
lesions and test the effects of an LM-targeting ligand on NP fate within the CSF. We 
identified CGKRK as an LM-targeting peptide in a mouse model of LM and showed 
CGKRK-targeted NPs exhibited altered distribution within the CSF compared to non-
targeted. Although we did not find any benefit from targeting to increase NP localization 
with LM, both targeted and non-targeted NPs were found to distribute through the CSF 
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and penetrate into LM lesions around the entire brain. These data support future 
development of drug loaded NPs for delivery to LM after IT administration and open 
new avenues for developing targeted systems via this route of administration.   
4.1. Introduction 
Medulloblastoma (MB) is the most common malignant pediatric brain tumor. 
Although MB arises in the cerebellum, approximately 1/3 of patients with MB exhibit 
Leptomeningeal Metastasis, which is characterized by the spread of the tumor through 
the cerebrospinal fluid (CSF) to the meninges surrounding the brain and spinal cord100–
102. Because LM cannot be surgically resected, it must be treated with a combination of 
high dose chemotherapy and cerebrospinal radiation. However, the blood-brain and 
blood-spinal cord barriers restrict CNS delivery of nearly all systemically administered 
drugs, and long-term outcomes for patients affected by LM remain poor106,107. Intrathecal 
(IT) injection of chemotherapies directly into the CSF has been used as an alternative to 
systemic administration, but poor distribution of active agents and toxicity has limited 
the efficacy of IT therapy for chemotherapy in the clinic111–113. Thus, new approaches are 
needed to overcome the limitations of free drug movement in the CSF and enable more 
effective LM treatments. 
In previous work, we have shown the ability of nanoparticle (NP) encapsulation 
to overcome the limitations of free drug distribution and improve drug efficacy following 
intravenous administration1. Additionally, we demonstrated the ability of 100 nm NPs 
administered by IT injection to be distributed by the CSF to achieve rapid and wide 
spread delivery along the neuraxis of healthy mice. While these data support the 
feasibility of IT administered NPs to be delivered to LM lesions, which are exposed to 
CSF, the known issues with neurotoxicity for free drug highlight the need to develop 
strategies that will target NP delivery to malignant cells while sparing healthy tissues. 
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Surface modification of nanoparticle (NP) drug carriers with targeting ligands 
has been proposed as a method to enhance NP drug delivery to specific tissues and cells 
through interactions with cell surface receptors or extracellular matrix proteins50,63,180,181. 
Depending on the ligand and NP system, targeting has shown potential to improve NP 
efficacy through prolonged NP retention65,69,70, increase payload delivery55,69,182, enhance 
NP internalization71,72 or direct NP fate to specific organelles73,74.  Despite the extensive 
use of targeted NP systems with most routes of administration, including 
intravenous23,63,69, intranasal45,183,184, and convection enhanced delivery50,185,186, the 
potential role of targeting for NPs administered by intrathecal (IT) injection remains 
unexplored. Access to the ligand’s target has been shown to be one of the major 
limitations to achieving targeting by intravenous administration55,64,187. The NP must 
first be carried by the blood to the target tissue and then extravasate out of the blood 
vessel before the ligand can interact with its target. Given that LM lesions are in direct 
contact with the CSF, the over-arching hypothesis for this work was that the distribution 
of a NP administered IT could be altered through surface modification with targeting 
ligands. 
No specific peptides have been previously identified to target LM. We therefore 
used bacteriophage biopanning to identify potential peptide candidates for LM targeting. 
Phage display allows for the expression of a wide diversity of exogenous peptides (109 or 
more unique sequences) and offers a powerful method to identify novel peptides that 
bind to LM lesions without necessitating pre-identification of a target receptor or 
molecule188–190. In addition to the potential peptides found by phage display, we also 
selected 3 known tumor-targeting peptides, CGKRK, CREQA and Angiopep, predicted to 
have targets expressed on the LM cells or within their microenvironment. The CGKRK 
peptide was discovered by in vivo phage display against squamous cell carcinoma191 but 
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has been shown to possess a high affinity for both the tumor neovasculature and the 
tumor cells in multiple solid tumors182,192–194. The proposed binding target of CGKRK, 
heparan sulfate, was previously shown to be upregulated within the blood vessels of 
human cerebral tumors and the extracellular matrix of primary MB tumors195,196. 
CREQA, often referred to as CREKA, was also discovered by in vivo phage display and 
was found to bind to fibrin deposits within the blood vessels and stroma of multiple 
tumor types197–200. The final peptide, Angiopep, was designed for specific interaction with 
the low-density lipoprotein-related protein 1 (LRP-1) on the blood-brain barrier201. In 
addition to high expression on brain vasculature, LRP-1 has been shown to be 
upregulated on tumor cells in both neuroblastoma202 and glioblastoma203 brain tumors.  
Here, we used a mouse MB model of LM to evaluate the capacity of 3 targeting 
ligands to bind to LM lesions ex vivo. Although all 3 of these peptides have been shown 
to improve NP interactions with multiple tumor types following intravenous 
administration, our studies are the first to assess their binding affinity for LM and to test 
their ability to improve NP interactions with LM lesions via IT administration. The 
identified LM-targeting peptide was attached to the surface of 100 nm PEGylated NPs by 
Michael-addition reaction. Finally, we tested the ability of targeting to alter NP fate in 
vivo in LM-bearing mice. Using a multispectral approach to allow for within subject 
comparisons, the distributions of targeted and non-targeted NPs were evaluated at 6, 24, 
48 and 1 week after IT administration. These studies are the first to test whether surface 
modification alters NP distribution following IT administration and bring us closer to 
our long-term goal of developing NP systems for LM-targeted chemotherapy in MB.  
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4.2. Materials and Methods 
 Materials 
100 nm carboxylate-modified FluoSpheresTM (red fluorescent, Ex/Em 580/605 
and yellow-green fluorescent, Ex/Em 505/515), SuperBlock Buffer, streptavidin-Alexa 
Fluor 405 and streptavidin- Alexa Fluor 633 were purchased from ThermoFisher 
Scientific (Waltham, MA USA). Endotoxin free water (<0.0050 EU/ml) purchased from 
G-Biosciences (St. Louis, MO USA) was used for all buffers and washes. Poly(ethylene 
glycol)-amine (mPEG-Amine, 2 kDa MW) and maleimide-poly(ethylene glycol)-amine 
(mal-PEG-Amine, 2 kDa MW) were obtained from Creative PEGWorks (Chapel Hill, NC 
USA). 5-FAM N-terminal modified peptides (>90% purity): ADARYKS, IVTQIPM, 
CGKRK, Angiopep (TFFYGGSRGKRNNFKTEEY) and CREKA (CRQKA), and 
unmodified CGKRK peptide (>95% purity) were purchased from GenScript (Piscataway, 
NJ USA). Mouse anti-human CD2:biotin (clone LT2) was bought from Bio-Rad 
(Hercules, CA USA). NeuroCult Mouse Basal Medium was purchased from STEMCELL 
Technologies (Cambridge, MA USA). All other chemicals and reagents were purchased 
from Sigma-Aldrich, unless otherwise specified. 
 Bacteriophage Biopanning for LM Targeting Peptides 
Phage biopanning was completed using the Ph.D.-7 Phage Display Peptide 
Library (New England Biolabs, NEB). We conducted 3 rounds of ex vivo screening, with 
each round consisting of 3 negative selections with freshly isolated neuraxis from 
healthy mice followed by a positive selection with a neuraxis isolated from mice with 
LM lesions. Neuraxis from healthy and LM bearing mice were freshly isolated before 
each incubation step and maintained in 1x PBS. For the first negative selection, 109 
phage were incubated for 1 hour at 37°C with healthy meninges under gentle shaking. 
After 1 hour, the meninge-phage solution was centrifuged and the supernatant 
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(containing unbound phage) was transferred to a fresh plate containing a new healthy 
neuraxis. After 3 negative selections, the resulting supernatant was incubated once with 
an LM bearing neuraxis. The phage bound to the LM meninges were eluted into DMEM 
with 1% FBS  using a dounce homogenizer and used for amplification for the next round 
of selections. All e coli. and phage cultures were performed as described in the NEB 
phage handbook. After 3 total rounds of selections, 48 phage clones were isolated and 
prepped for Sanger Sequencing using a QiaPrep mini-kit following the provided 
protocol.  
 FluoSphere PEGylation and Peptide Conjugation 
Non-targeted carboxylate-modified FluoSphereTM (FS, 100 nm) nanoparticles 
were covalently modified with mPEG-Amine (2k Da MW) by carboiimide chemistry. FS 
in 500 µl aliquots were washed to remove the sodium azide using 0.5 ml Amicon-Ultra 
centrifugation filters (10k MWCO). Retained FS were resuspended with water bath 
sonication in 10 ml MES buffer (10 mM, pH 6). mPEG-amine (5x molar excess) was 
added to the FS and allowed to stir for 15 min. Next, 4 mg 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) was added to the stirring solution. The 
reaction was left stirring for 3 hrs at room temperature before quenching with excess 
glycine (100 mM) for 30 min. Unreacted PEG, EDC, and glycine were removed with 3 
centrifugation washes using 15ml Amicon-Ultra centrifugation filters (100k MWCO), and 
resuspended to 20 mg/ml in 1x PBS for storage at 4°C until use. Targeted FS (CGKRK-
FS) were produced by the same methods except 10% w/w mal-mPEG-amine was added 
to the reaction. Following the initial washes to remove unreacted PEG, the FS were 
diluted in 5 ml MES buffer (200 mM, pH 5.5) and CGKRK peptide (5x molar excess) was 
attached via thiol-maleimide coupling for 1 hour at room temperature. Unreacted 
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peptide was removed by 3 additional centrifugation washes before resuspension to 20 
mg/ml in 1x PBS.  
 FluoSphere Characterization 
FS size and zeta potential was measured in 1 mM KCl before and after PEGylation 
using the NanoBrook 90Plus Zeta (Brookhaven Instruments, Holtsville, NY USA). Each 
sample was measured 10 times and averaged across 3 repeats. Peptide conjugation was 
confirmed by 1H NMR. Lyophilized FS samples before and after peptide conjugation 
were dissolved at 1 wt% in CDCl3 and analyzed by 1H NMR (400 MHz Varian). 
 In Vivo 
All procedures and animal care practices were performed in accordance with the 
Barrow Neurological Institute’s Institutional Animal Care and Use Committee. NOD 
SCID gamma (NSG) mice (Jackson Labs, Bar Harbor, ME USA) were used for all in vivo 
experiments. 
 Leptomeningeal Metastasis Model 
Here, we utilized a novel genetically engineered mouse model of MYC-driven MB, 
developed in the Wechsler-Reya Lab204 (See citation for detailed analysis). Briefly, this 
tumor model (referred to as MP tumors) uses postnatal cerebellar stem cells from C57 
mice transfected to over-express MYC and dominant-negative mutant Trp53. MP tumors 
are serially passaged orthotopically in the cerebellum of mice to maintain key 
histological and genetic features of Group 3 MB. These tumors also express luciferase 
and a truncated version of human CD2, allowing for bioluminescent monitoring of tumor 
growth and immunofluorescent tracking of cells. 
 LM seeding of MP tumors was induced by injection of MP cells directly 
into the CSF via cisterna magna. Isoflurane (0.5-2%) was used to maintain proper depth 
of anesthesia (confirmed by toe pinch) throughout the procedure. Mice were mounted on 
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a stereotaxic frame (Kopf Instruments, Tujunga, CA USA) on top of an infrared heating 
pad. After shaving the fur, a sterile surgical site was prepped over the brain and neck 
using 3 alternating passes of betadine and 70% ethanol. A ~ 1 cm incision was made 
along the back of the neck before dropping the head from the bite bar to a 60° with the 
body. Blunt dissection was used to carefully part the muscle to expose the membrane 
covering the cisterna magna. An ice cold Hamilton syringe (29 gauge, 30° beveled 
needle) containing 10k MP cells in a 1:1 mixture of NeuroCult media and growth factor 
reduced Matrigel was inserted to a depth of 1.3 mm through the membrane, and the cells 
were injected over 1 min. The needle was left in place for an additional 2 min to reduce 
backflow. Staples were used to close the incision, and triple antibiotic ointment was 
applied over the wound. All animals received a subcutaneous injection of Buprenorphine 
SR (1 mg/kg) prior to surgery, and ibuprofen was provided in their water for 1 week to 
reduce pain.  
 Tumor Tracking 
Tumor seeding and growth was monitored by bioluminescent imaging using the 
Xenogen IVIS spectrum imaging system, as previously described1. Briefly, mice were 
injected subcutaneously with 150 mg Luciferin/ kg 10 min prior to imaging, under 2% 
isoflurane. Tumor size was measured using the IVIS Living image software by drawing 
an ROI around each tumor signal. 
 FluoSphere Administration 
FS were administered to CSF of LM bearing mice by the same procedure as 
tumor cells as described in 4.3.5, with minor alterations. In isoflurane anesthetized mice, 
a Hamilton syringe (29 gauge, 30° beveled needle) was used to inject 2 µl 1:1 mix of non-
targeted FS (yellow) and CGKRK-FS (red) (20 mg/ml in PBS) over 1 min at a depth of 1 
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mm in the cisterna magna. The needle was left in place for 2 min after injection to reduce 
backflow, before closing the wound. 
 Neuraxis Collection 
Mice were sacrificed at 6, 24 and 48 hrs, and 1 week (n=3-4/ time point) post FS 
administration, to examine FS distribution and localization with LM lesions. Mice were 
sacrificed by cardiac perfusion with 15 ml heparinized PBS (1000U/ml) followed by 10 
ml 4% paraformaldehyde (PFA). The entire brain and spinal column, from nasal sinuses 
to sacral spinal region, was isolated by removing the majority of muscle and skin but 
leaving the bone left intact to preserve the integrity of the leptomeninges. The neuraxis 
was post-fixed in 4% PFA for an additional 24 hrs, before decalcification of the bone in a 
4% HCl and 4% Formic Acid v/v solution, replaced daily, for 5 days. Following 
decalcification, the neuraxis was transferred to a 30% (w/v) sucrose solution for 48 hrs 
for cryoprotection. The brain and spinal cord were separated at the C1 vertebrae. One 
hemisphere from each brain was embedded in OCT and frozen at -80° C before slicing 
into 20 µm sagittal sections. 
 Ex Vivo CGKRK-FS Targeting 
To confirm peptide functionality after conjugation to the FS, brains were isolated 
from LM bearing mice and incubated ex vivo with either non-targeted or CGKRK-
modified FS. Each brain was incubated for 4 hrs with 0.2 mg FS at 37°C with rocking. 
Each sample was washed 3 times with 5 ml PBS for 20 min with agitation to remove 
unbound FS, before being fixed in 5 ml 4% PFA for 24 hours. 30% sucrose for 48 hrs was 
used to cryoprotect the brains before being embedded in OCT and frozen at -80° C for 
slicing. 
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 Image Collection 
A Zeiss LSM confocal microscope was used for all imaging. Laser intensities and 
gains were kept constant within each experiment. It was confirmed that the particles did 
not show spectral overlap under our imaging conditions. Using mixtures of red and 
green FS, the gains for comparing the targeted and non-targeted FS were set such that 
the total fluorescence measured with ImageJ from both formulations would be 
equivalent at equal concentrations. 
4.3. Results and Discussion 
 Bacteriophage Biopanning and Free Peptide Binding to LM 
In chapter 3, we showed the safety and feasibility of 100 nm PEGylated NPs to 
achieve widespread distribution along the neuraxis in healthy mice, following 
administration into the CSF through the cisterna magna. Surface modification of NPs 
with targeting ligands has been extensively studied for most routes of administration, 
including intravenous23,63,69, intranasal45,183,184, and convection enhanced delivery50,185,186, 
but to our knowledge, never for IT delivery. Since a cell’s microenvironment is known to 
affect both protein expression and receptor localization205–208, it is important to test 
ligands against cells as close to their native state as possible. Thus, we utilized ex vivo 
incubation for our bacteriophage biopanning. Although some of the outermost meninges 
are lost during brain removal, the ex vivo brains are expected to better maintain native 
cellular and extracellular architecture of the LM lesions compared to in vitro. 
Additionally, we wanted to isolate peptides displaying minimal interaction with healthy 
tissue to reduce off target NP delivery. Since our data in chapter 3 suggests 100 nm NPs 
have minimal penetration across the pia mater into the CNS parenchyma, we used 
healthy neuraxis to select against peptides with an affinity for healthy meningeal cells 
and the arachnoid trabeculae. From the 3 rounds of biopanning, we found the peptides 
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ADARYKS and IVTQIPM to appear the most frequently and were selected for further 
evaluation. To evaluate the ability of the identified and pre-selected peptides to bind to 
LM, we incubated fluorescently labeled ligands, ADARYKS, IVTQIPM, Angiopep, 
CGKRK, and CREKA, with brains that were extracted from LM-bearing mice. Ideally, we 
would have tested peptide binding by directly injecting fluorescently labeled peptides in 
vivo, but issues with fluorescence stability through the decalcification process prohibited 
our ability to interpret the results. While all 5 of the peptides were found to bind to LM 
cells in both large and small lesions, CGKRK consistently displayed the greatest signal 
localization with CD2+ tumor cells (Figure 4.1). Using healthy brain controls, we also 
tested peptide binding specificity for LM compared to non-specific binding to healthy 
meninges. While all the peptides exhibited some degree of non-specific binding to 
healthy brain, minimal to no signal was seen in the CGKRK brains without increasing the 
image gain compared to the other peptides (Figure 4.1). Qualitatively, CGKRK exhibited 
both the lowest overall binding to healthy and the greatest difference in binding between 
healthy and LM cells among the peptides. Thus, we moved forward with the attachment 
of CGKRK to the FS. 
 FS PEGylation and Peptide Conjugation Characterization 
Amine-PEG was covalently bound to the FS surface by EDC chemistry. DLS 
measurements showed an expected increase in average FS diameter from 100 to 108 nm 
and a shift in zeta potential from -45 mV towards a more neutral charge of -5.3 mV 
following the conjugation of PEG to the surface. CGRKR was attached to maleimide 
functionalized PEG on the FS surface via a Michael-type addition reaction with the free 
thiol on the N-terminal cysteine. The attachment of CGKRK also produced a further 
increase in size from 108 to 113 nm and caused a switch in zeta potential from -5.3 to 9.7 
mV. The shift in FS zeta potential from negative to positive following peptide attachment 
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is expected to be caused by the positive charge of the KRK motif, suggesting successful 
attachment. To further confirm successful attachment of the CGKRK peptide, we ran 1H 
NMR on maleimide functionalized FS before and after peptide conjugation (Figure 4.2). 
Although we were unable to directly detect the peptide by 1H NMR, this is likely due to 
the low peptide content relative to PEG. As a surrogate, prior works conjugating similar 
short peptides have shown changes in the maleimide peak to accurately reflect peptide 
attachment197,209. A large peak at 3.6 corresponds to the successful attachment of PEG. 
Prior to peptide conjugation, there was a small peak at 7.9, confirming the presence of 
maleimide functionalized PEG, and the observed 30% decrease in maleimide after 
conjugation confirms successful CGKRK attachment.  
 In Vivo CGKRK-FS Targeting 
The ability of CGKRK targeting to increase the delivery of FS to LM lesions was 
evaluated in LM bearing mice at 6, 24, 48 hours and 1 week after intracisternal 
administration. Due to the heterogeneous distribution of LM lesions between mice and 
the known potential for lesions to alter CSF flow210, we were motivated to compare the 
distribution of targeted and non-targeted FS mixtures within the same subjects using a 
multispectral approach: differently colored FS were mixed together and administered to 
a single subject. We first confirmed that non-targeted red and green FS, when mixed 
together at the same concentration and administered to a single subject, exhibited 
equivalent distribution around the brain 2 hours after injection independent of color 
(Figure 4.3). Interestingly, we observed almost complete co-localization of the 2 FS 
signals. To ensure the observed signal overlap was not an artifact of the decalcification 
process or an issue of spectral overlap, we confirmed non-targeted FS distribution was 
significantly different between colors when FS were administered 2 hours apart instead 
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of simultaneously (Figure 4.3). These experiments confirm that FS color does not affect 
distribution, and, under the right conditions, we can observe differences in distribution.  
The next experiments involved mixing targeted and non-targeted FS together to 
assess their distribution in LM bearing mice. Both CGKRK- and non-targeted FS 
distributed away from the injection site, through the meninges and around the entire 
brain. Surprisingly, the gross distribution pattern around the brain for both targeted and 
non-targeted FS was similar to the overall distribution patterns we previously observed 
for non-targeted FS administered to healthy mice (Chapter 3 and Figure 4.4). 
Specifically, the FS showed preferential distribution to the ventral brain, minimal 
delivery to the prefrontal cortex region of the SAS, and increased delivery to the 
supracerebellar cistern and pituitary recess. These data demonstrate that the presence of 
the lesion is not an impediment to NP movement through the leptomeningeal space. In 
all samples, both targeted and non-targeted FS were found to directly interact with LM 
lesions. In general, the intensity and patterns of FS delivery across lesions was found to 
vary significantly, both between mice (Figure 4.5A and B) and within the same subject 
(Figure 4.5 B and C). Although the FS were found to penetrate into most lesions, we did 
observe instances where the FS appeared to be confined to the meninges around the 
lesions (Figure 4.5D). Since CSF movement is expected to carry the FS through the 
SAS113,211, the observed similar FS distribution compared to healthy would suggest the 
LM lesions were not disrupting the macro patterns of CSF flow around the brain. 
However, the variability in FS localization across lesions indicates the lesions were still 
altering the local mixing of CSF around them96. 
In our evaluation of targeting effects, we observed that the majority of detectable 
signal overlapped between targeted and non-targeted FS, both around the brain and 
within LM lesions. Although differences were observed in the distribution of targeted 
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versus non-targeted FS following IT injection (i.e., Figure 4.6), these differences were 
subtle, involving small fractions of weakly fluorescent FS. Targeting ligands have the 
potential to improve the localization and internalization of attached cargo through 
interactions with cell surface receptor or extracellular matrix proteins, which has been 
demonstrated in a number of other model systems 50,63,180,181. Our over-arching 
hypothesis was that the presence of targeting ligand on the surface of NPs would 
enhance NP localization with LM. While the data presented here failed to show robust 
support of this hypothesis, several possible explanations exist. 
First, it is possible that our approach for evaluating FS distributions does not 
possess the sensitivity needed to observe differences in targeted and non-targeted 
formulations. Our efforts to quantify differences in FS distribution were severely limited 
by the significant heterogeneity observed in FS intensity. To allow for accurate 
fluorescence quantification, signal gains were carefully adjusted to allow imaging 
parameters to be maintained across samples. The variability in FS delivery across a 
broad signal range within each lesion required adjustment of microscope settings to 
avoid saturation of the highest signals. This need to avoid saturation also inhibited our 
ability to detect and accurately quantify the smaller populations of low signal intensity 
FS within the lesion, where potential differences could be qualitatively observed. 
Similarly, the difference in magnitude of FS delivery across lesions meant the 
maintenance of imaging settings resulted in those lesions with lower total delivery to 
almost appear void of FS, but clear FS localization is seen at higher gains (e.g., Figure 
4.7). Thus, it is possible that a smaller population of FS (e.g., non-aggregated FS) are in 
fact distributing differently, but that this low signal population is being lost in the 
visualization of brighter FS deposits. Better imaging techniques and/or drug distribution 
studies would be needed to explore this possibility. 
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As a second consideration, it is possible that CGKRK functionality after FS 
attachment was insufficient to achieve adequate binding with the LM cells. The peptide 
must be presented in both the proper orientation and be accessible beyond the PEG layer 
to allow for binding212,213. To further test CGKRK-FS functionality, we compared the co-
localization of targeted versus non-targeted FS after ex vivo incubation with LM bearing 
brains. While we were able to observe differences in localization ex vivo, the effects of 
targeting were not as robust as the free peptide (Figure 4.8). These data indicate that 
some functionality of CGKRK is lost upon attachment to the NP surface. Future work 
modulating the PEG linker length213 and peptide density212 on the FS surface could 
potentially increase the binding affinity of CGKRK-FS to produce stronger interactions 
with LM cells. Given that we never observed any differences in distribution between 2 
non-targeted FS in vivo, the minor differences observed between target and non-target, 
both in vivo and ex vivo, suggests the peptide was active. However, we cannot exclude 
the possibility the differences observed were actually caused by non-specific interactions 
due to the change in surface charge between our non-targeted and targeted particles. 
Future work would need to use a scrambled peptide with equivalent charge to our 
targeting peptide to differentiate between specific peptide-receptor interactions versus 
non-specific charge mediated alterations to NP distribution.   
Third, the fact that we do not observe major differences in NP localization does 
not exclude the possibility that delivery of a NP payload could be altered. Prior works 
showing improved CGKRK-mediated targeting to tumors by intravenous delivery were 
tracking the distribution of DiR, a lipophilic fluorescent dye, encapsulated within the 
NP182,192,214. While encapsulated dyes like DiR are well retained within the NP in aqueous 
environments, they are not expected to be retained in vivo. We have previously shown 
when NPs interact with cells, DiR can be directly transferred into the lipid cellular 
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membrane in the absence of NP internalization, and remain after the NP has cleared69. 
The FS used here are internally dyed such that they do not exhibit direct transfer or 
leaching of the dye. Therefore, the prior CGKRK studies only definitively tell us the 
targeting was able to increase NP payload (DiR) delivery to the tumors but cannot 
determine if the actual NP fate was altered. In the absence of internalization, we have 
previously shown targeting ligand interactions with their receptor can still facilitate NP 
association with the cell but only for short periods under convective flow conditions215, 
and that these enhanced cellular interactions can significantly increase NP payload 
delivery69. Thus, CGKRK mediated FS interactions with LM cells could have prolonged 
their association with cells, which would enable an increase in payload delivery, even 
though targeting was unable to overcome the convective forces of the CSF to significantly 
alter NP fate. 
As a final consideration, it is important to acknowledge that our data support the 
alternative hypothesis that NP biophysical factors other than targeting are potentially 
more important for governing NP distribution by the convective forces of the CSF when 
NPs are administered IT. Similar observations on NP distribution following IV delivery 
have led to active discourse and some disagreement in literature regarding the 
significance of targeting in governing NP tissue distribution through the blood 
circulation relative to other major factors, such as NP size, surface charge, shape, and 
flexibility55,64,187. There is a growing body of evidence demonstrating that targeting does 
not produce dramatic changes in NP localization when measured at static time points. 
However, for the reasons outlined above, the lack of major change to NP localization by 
targeting does not exclude the possibility that drug delivery can still be impacted to 
provide an improvement in therapeutic efficacy. 
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4.4. Conclusions 
Here, we identified CGKRK as an LM-targeting peptide and tested the ability of 
both targeted and non-targeted NPs to reach LM lesions after IT administration.  We 
show CGKRK possessed strong binding and specificity for LM lesions and was able to 
increase NP interactions with LM lesions ex vivo. Although we were able to observe 
qualitative alterations to the NP distribution due to CGKRK targeting, we failed to 
observe a significant increase in targeted NP localization with LM in vivo. Regardless of 
targeting, we found 100 nm NPs administered IT, via the cisterna magna, were able to 
localize with LM lesions and penetrate throughout the tumors within hours of 
administration. These studies highlight the potential for NP drug carriers to deliver 
chemotherapy to LM after IT administration.  
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4.5. Tables and Figures 
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Figure 4.1: 5-FAM labeled peptide binding to LM lesions and healthy meninges ex vivo. 
The relative binding affinity of AngioPep, CGKRK, CREKA, IVTQIPM, ADARYKS for LM 
lesions were compared after ex vivo incubation with LM bearing brains. (Top panels)  All 
5 peptides (green) were found to localize to LM lesions (blue) with CGKRK showing the 
greatest binding across lesions. (Bottom panels) CGKRK also displayed the least non-
specific binding to healthy meninges following ex vivo incubation with healthy brain 
controls. Cell nuclei (DAPI) are shown in blue. Scale bar = 100 µm 
 
Figure 4.2: FS characterization by NMR. 1H NMR spectra collected pre and post-CGKRK 
conjugation. A 30% reduction in maleimide (δ = 7.9) relative to PEG (δ = 3.6) was 
observed after peptide conjugation.  
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Figure 4.3: Testing the tracking of multiple FS formulations in a single mouse. (Upper 
panels) The simultaneous injection of a 1:1 mix of green and red non-targeted FS into the 
cisterna magna of mice resulted in complete signal co-localization between the 2 FS 
around the brain. (Lower panels) However, when the 2 colored FS were injected 2 hours 
apart, obvious differences in distribution could be observed. Cell nuclei (DAPI) are 
shown in blue. Scale bar = 100 µm 
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Figure 4.4: Targeted and non-targeted FS distribution around LM bearing brains. 
Sagittal brain slices from 6 (A) and 24 (B) hours after IT injection of CGKRK-targeted 
(red) and non-targeted (green) FS in LM bearing mice. Both FS were found to 
preferentially distribute along the ventral brain with minimal delivery to the prefrontal 
cortex region of the SAS and strong delivery to the supracerebellar and pituitary cisterns. 
The same patterns were also observed at 48 and 1 week after injection (not shown).  
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Figure 4.5: Targeted and non-targeted FS localization with LM lesions in vivo. Both 
CGKRK-targeted (red) and non-targeted FS (green) were found to directly interact with 
both large (A) and small (B) LM lesions (blue). While some lesions appeared to have 
more targeted (red arrows) versus non-targeted (green arrows) FS, these patterns varied 
both between mice (A vs B) and within the same mouse (A vs C). (D) Some lesions were 
also found to exclude the FS to the meninges around the lesion. Scale bar = 100 µm. 
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Figure 4.6: Detecting small differences in targeted and non-targeted FS localization in 
vivo. (A) Targeted (red) and (B) non-targeted (green) FS signals were found mostly co-
localize within LM lesions (C). Within some regions, faint signals from small populations 
of both targeted (red arrows) and non-targeted (green arrows) FS could be seen exclusive 
of the other. (D) Zoomed in image of C showing regions with greater red targeted FS 
signal. Scale bars = 100µm. 
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Figure 4.7: Limitations of FS detection.  Maintenance of imaging setting across lesions 
(blue) meant those lesions with lower total FS delivery (A) to appear void of FS 
localization but (B) increasing the digital gain shows clear FS localization. Scale bars = 
100µm. 
 
Figure 4.8: CGKRK-FS targeting ex vivo. Targeted-FS (A) showed a minor qualitative 
increase in localization with CD2 (blue) compared to non-targeted (B).  Scale bars = 
100µm. 
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Conclusions and Future Directions 
This final chapter summarizes the results achieved towards each of the specific 
aims and discusses the potential future directions to take these studies. 
5.1. Specific Aim 1: Test the capacity of NPs to solubilize and enable the 
effective IV delivery of an otherwise intolerable lipophilic 
chemotherapy. 
The first research chapter describes the fabrication of CPT-loaded PLGA NPs for 
intravenous delivery to orthotopic GL261 glioma tumors. PLGA is a biocompatible and 
biodegradable polymer capable of forming nanoparticles for the encapsulation and 
subsequent controlled release of a wide range of therapeutics. The hydrophobic core of 
PLGA NPs is especially effective at encapsulating hydrophobic and lipophilic small 
molecules like CPT. We demonstrate that a hydrophobic payload encapsulated within the 
PLGA NPs was delivered to the tumor core at ~10x higher levels compared to healthy 
brain. Payload delivery to the tumor core was higher for larger, more advanced tumors, 
indicating that interstitial pressure is not a barrier to effective small molecule delivery 
from NPs. Efficient loading of CPT was achieved at nearly 10 wt% in the NPs with 
sustained release occurring over 24 hrs. CPT solubilization within PLGA NPs reduced 
drug toxicity, enabling safe and tolerable intravenous administration at twice the free 
drug dose. This higher tolerable dose combined with the accumulation of NPs within the 
leaky tumor vasculature resulted in greater CPT activity within NP treated tumors 
compared to free drug. While the growth of intracranial GL261 tumors was unaffected by 
free CPT or blank NP (no drug), CPT-NPs administered at the max tolerable dose 
significantly slowed tumor growth and prolonged survival. These studies demonstrated 
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the solubilization of a lipophilic drug within PLGA NPs can improve drug tolerability and 
efficacy.  
5.2. Specific Aim 2: Characterize the ability of NPs to be distributed by the 
convective flow of CSF to identify engineering opportunities for the 
design of IT NP systems.  
The second research chapter characterizes the fate of 100 nm PEGylated NPs 
after direct administration into the CSF through injection into the cisterna magna of 
healthy mice. NP distribution was evaluated both in vivo using an IVIS imaging system 
and ex vivo in tissue slices using confocal microscopy. Both methods showed the rapid 
distribution of the NPs along the entire neruaxis, from olfactory bulb to sacral spinal 
cord, within 2 hours of injection, confirming that NPs are effectively carried by the 
convective movement of the CSF. Although the NPs’ 100 nm diameter prevented any 
significant penetration into the brain or spinal cord parenchyma along perivascular 
routes, they were capable of following the meninges deep into the sulci of the brain and 
along nerve bundles. Despite the turnover of CSF multiple times a day, a significant 
population of NPs was retained within the SAS around both the brain and spinal cord for 
over 3 weeks post administration. NPs were found to clear from the brain CSF across the 
cribriform plate into the nasal mucosa, but NP delivery along the spinal cord did not 
significantly change over the 3 weeks. We also observed distinct regional distribution of 
the NPs due to the unique architectures of the brain and spinal cord. While NPs were 
relatively uniformly distributed around the circumference of the spinal cord, a significant 
preference for ventral distribution was observed around brain. Additionally, a high 
concentration of NPs was consistently found within the supracerebellar cistern and the 
pituitary recess. These results identified opportunities to tune NP drug release to take 
advantage of their prolonged retention and potential distribution patterns that would be 
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expected to influence therapeutic efficacy. Overall, this study demonstrated the potential 
of 100 nm NPs to be transported by the CSF to achieve rapid, wide spread delivery along 
the neuraxis. 
5.3. Specific Aim 3: Identify a targeting ligand for LM cells and investigate 
the ability of targeting to alter NP fate after CSF administration. 
This final research chapter discusses the identification of an LM targeting peptide 
and the effects of targeting on NP fate following IT administration. We evaluated the 
capacity of 3 targeting ligands to bind to LM lesions ex vivo, identifying the peptide 
CGKRK to have the greatest relative affinity and specificity for LM lesions compared to 
healthy CNS tissue and meninges. Following successful attachment to the NPs, we 
evaluated the fate of CGKRK-modified relative to non-targeted PEGylated NP after co-
administration through the cisterna magna of LM bearing mice. Both NPs were 
distributed by the CSF through the meninges around the entire brain and were observed 
to interact with LM lesions. The overall distribution of the NPs around the brain was 
found to reflect similar patterns as those observed in Chapter 3 for non-targeted NPs in 
healthy mice, including strong ventral distribution, minimal distribution to the frontal 
cortex region, and high NP signal within the supracerebellar and pituitary cisterns. Total 
NP delivery across LM lesions was found to vary significantly, both within and between 
mice, but did not appear to be dependent on the size of the lesion. While the similar 
distribution compared to healthy suggests the LM lesions did not cause significant CSF 
flow disturbances on a macro scale around the brain, the highly variable FS delivery to 
lesions would indicate the lesions caused their own unique local CSF mixing. Although 
we were able to observe minor qualitative differences in distribution between the 
targeted and non-targeted NPs, the significant majority of the 2 NPs’ signal were found 
to co-localize with each other, both around the brain and within LM lesions. No clear 
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benefit in LM localization of NPs was seen from CGKRK targeting in vivo. When we 
tested the functionality of CGKRK-NPs ex vivo with LM brains, we were able to observe a 
small increase in LM binding relative to non-targeted NPs. However, the binding 
capacity of CGKRK-NPs was clearly diminished compared to free peptide. Taken in sum, 
we hypothesize CGKRK was active after NP attachment, and the minor differences in NP 
distribution were due to increased NP interactions with LM cells; the overall NP fate was 
governed by the convective forces of the CSF. Regardless of targeting, we show IT 
administered NPs were able to localize with and penetrate into LM lesions, 
demonstrating their strong potential as a future system for delivering lipophilic 
chemotherapies to LM.  
5.4. Future Directions 
 Improving Tracking of NP Distribution in the CSF 
The work presented in this thesis provided us with the some of the first 
investigation into the engineering opportunities and potential barriers for the 
development of NP drug carriers for IT administration. Although we were not the first to 
inject NPs into the CSF83–86,166,216,217, the collective understanding of how NPs move 
within the SAS is severely lacking, and our work begins to address this gap. Compared to 
the 175 intravenous NP papers already published this year on PubMed, there are only 3 
IT nanoparticle papers. The work in Chapters 3 provides the first information into the 
distribution kinetics and fate of 100 nm PEGylated NPs injected IT. Our data highlights 
the potential for 100 nm NPs to be rapidly distributed throughout the entire meninges of 
the neuraxis by the convective flow of CSF and, to our surprise, be retained for over 3 
weeks, despite the multiple CSF turnovers each day99. NP concentration was found to be 
nearly constant over the 3 weeks. We also found NPs distributed to the meninges along 
exiting nerve roots, which suggests potential opportunities to design a NP system to 
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provide sustained delivery of therapeutics for the treatment of diseases affecting motor 
neurons, such as amyotrophic lateral sclerosis. However, the localization with the nerves 
could also become an issue for chemotherapy delivery due to potential toxicity and nerve 
pain. Similarly, the heterogeneous distribution we observed around the surfaces of the 
brain were on an order of magnitude that could impact therapeutic efficacy or lead to 
toxicity. While these studies deepened our understanding of 100 nm NP movement 
within the CSF, they only provided the first snapshots into the potential of NPs for IT 
therapies. These initial observations emphasize that toxicity may be a key concern for 
designing NP systems for IT administration, and future studies could focus on 
engineering drug retention or NP localization to circumvent potential toxicity.  
The work presented in Chapters 3 and 4 highlighted key limitations to our 
approach of looking at static endpoint analysis. The small volume and inaccessibility of 
the IT space combined with complexity of the CNS geometries restricted our ability to 
quantify over the meninges large surface area, leaving much of our data to be 
observational. Additionally, the heterogeneity of LM combined with our poor 
understanding of the complex interplay between LM lesions and CSF movement made 
the variability of static endpoint analysis difficult to interpret. Thus, for the future 
studies discussed in the following sections, we propose the use of Positron Emission 
Tomography (PET) to allow for quantitative, 3-dimensional (3D) analysis of 
radiolabeled-NPs (or drugs) after IT administration. PET is particularly sensitive in 
concentration quantification, but the limitations of PET’s spatial resolution to about 1-2 
mm218 make the use of rat models in future work a better choice than mouse. PET could 
further be combined with the use of magnetic resonance imaging (MRI) to visualize the 
distribution of LM lesions along the neuraxis, allowing us to directly correlate NP or drug 
delivery with LM lesions219,220.  
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 Drug Delivery and Efficacy in LM 
Our overall goal for IT administered NPs is to improve drug delivery to LM in 
MB. In Chapters 3 and 4, we showed 100 nm NPs achieve widespread distribution along 
the neuraxis and penetrate into LM lesions. However, as discussed, the encapsulated 
payload will have its own fate compared to the intact NP. Although we did not observe a 
significant change in NP fate with CGKRK targeting, as discussed in Chapter 4, it is still 
possible for the ligand to prolong NP-cell interactions resulting in increased payload 
delivery. Before returning to in vivo studies, we would be interested to test the effects of 
altering ligand density, or PEG length, using an in vitro flow cell, to improve the strength 
of peptide binding213,221. By radiolabeling the drug, the use of PET-MRI should enable us 
to track drug delivery to localized groups of lesions and monitor the tumors responses 
within the same subject222,223. Therapeutic efficacy is the ultimate goal and test of a NP 
system. One of the believed limitations of current IT therapies is a lack of penetration 
into the lesions; therefore, our observation of NP penetration into most lesions could 
provide a significant benefit. Using post-survival tissue, it would be important to look for 
markers of drug activity within the lesions to see how well the drug is transported into 
the core of lesions. Similarly, we would want to look for drug activity in the healthy 
parenchyma, as the lack of penetration of the NPs into the parenchyma is expected to 
help reduce drug toxicity to healthy tissue. Current treatments are largely ineffective at 
providing a significant survival benefit in LM. Together, these studies would expand our 
understanding into the requirements to achieve cellular and lesion responses to 
treatment and how those responses translate to survival.  
To expand these studies, we would also propose to further develop our 
nanoparticles for prolonged release. While the ~24 hr release of CPT from PLGA NPs 
was sufficient to improve tolerability in chapter 2, the burst release profile observed for 
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these NPs would not be able to fully take advantage of the prolonged 3 week retention 
observed for NPs within the CSF. At the 100 nm size, we would not expect to achieve 
adequate drug concentrations for 3 weeks but alterations to NP design could still enable 
prolonged release compared to the PLGA NPs. For example, the addition of a lipid 
monolayer around the PLGA NPs has previously been shown to prolong the release of 
docetaxol from 3 days to over 5 days224. More complex release mechanisms utilizing 
covalently attached drug could also be tested. For example, attachment of drugs by 
radiation liable linkers could enable drug release only during radiation treatment225. 
Attachment of radio-sensitizing drugs by this method would be expected to enhance 
radiation efficacy and potentially reduce the necessary dose. We could also explore larger 
diameter NPs which could allow for larger drug doses to be delivered in a single 
injection. Considering we found 10 µm FS are able to transverse the leptomeninges, 
larger NPs may be able to achieve similar NP distributions as the 100 nm NPs. In 
conclusion, this body of work establishes multiple drug delivery strategies to intracranial 
tumors by IV or IT administration. Our future work will focus on identifying the 
necessary NP properties for the delivery of specific drugs to LM in MB. 
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